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Abstract  
Background: Intravenous aminophylline is used to treat childhood asthma 
exacerbations. Children who receive aminophylline have serum drug levels 
measured, due to its purported narrow therapeutic range and variable 
clearance rates. The results of therapeutic drug monitoring are used to inform 
subsequent clinical decisions such as dosage. It is not known whether these 
practices maximise the safety and efficacy profile of aminophylline, and the 
mechanisms underlying the interindividual variation in clearance rates are 
poorly understood. 
Aims: To assess the evidence base of current aminophylline prescribing 
practices, and to investigate the mechanisms underlying the variability 
aminophylline clearance rates.  
Methods: Two systematic reviews were undertaken to investigate 
aminophylline prescribing practices. The first review compared outcomes of 
children who achieved serum theophylline concentrations between 10-20mg/l 
with those who did not, and the second review compared different dosage 
regimens of intravenous aminophylline. An audit of adherence to 
aminophylline prescribing practices was performed, with subsequent 
pharmacokinetic analysis. Finally, a pilot cohort study was used to investigate 
the role of genetics in the variability of aminophylline clearance. 
Results: The systematic reviews found a poor correlation between serum 
drug levels, dosage and clinical outcomes in children receiving intravenous 
aminophylline. Good adherence to prescribing practices was found in our 
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audit, however the effectiveness of treatment for acute asthma is no worse if 
the therapeutic range is not achieved in the first 12 hours of treatment. The 
cohort study has not yet recruited sufficient participants to assess the effect 
of genes on aminophylline clearance.  
Conclusion: Current dosage and monitoring practices of intravenous 
aminophylline in childhood asthma exacerbations have a poor evidence base. 
Measuring aminophylline following administration may be unnecessary, due to 
the poor relationship between serum drug levels and clinical outcomes, and 
current dosing strategies may not maximise the benefit of the drug. Most 
children who receive loading doses do not achieve therapeutic levels, and the 
mechanisms underlying this variability remain poorly understood.  
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Chapter 1: Introduction 
 
1.1 Background 
Asthma is an incurable disease with serious consequences for children and 
their families. Each year there are 25,000 paediatric asthma admissions to 
hospital in England, resulting in significant impairment, reduced quality of life 
for patients and a wider impact on society [1]. The prevalence of asthma is 
rising [2], with global asthma mortality projected to increase well into the 21st 
century [3]. 
 
All children with asthma are at risk from developing severe exacerbations [4], 
which have detrimental effects on the wellbeing of children. Exacerbations of 
asthma are highly distressing, requiring hospital admission and treatment 
with potentially harmful medicines. Regular exacerbations may result in 
structural alterations of the airways leading to progressive decreases in lung 
function and permanent damage to the respiratory tract [5-8]. Frequent 
asthma exacerbations can have a long-term impact on a child’s education due 
to school absence [9]. The National Health Service spends in excess of £1 
Billion on asthma each year, with further economic costs incurred by loss of 
parental earnings from days off work [10].  
 
Intravenous aminophylline is one of several medicines used to treat acute 
exacerbations of asthma. Despite being one of the oldest antiasthmatic drugs 
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still in use, little attention has been paid to its optimum dosage and 
monitoring strategies in children, meaning patients may not receive the full 
benefit of the drug. Individuals respond to aminophylline differently, with 
large variations in clearance rates and clinical efficacy in children [11]. The 
mechanisms underlying interindividual variation in adults and children are 
poorly understood. This results in an unpredictable clinical response to 
aminophylline, which may result in therapeutic failure in some patients and 
toxicity in others. This lack of knowledge means it is difficult to make 
informed decisions about aminophylline therapy.  
 
This work aims to review the evidence base for the current dosing and 
monitoring strategies of intravenous aminophylline. This is a vital step in 
improving asthma outcomes in children. This chapter reviews the current 
understanding of asthma pathophysiology and the management of 
exacerbations in children. The pharmacokinetics and pharmacodynamics of 
aminophylline will be outlined and the evidence surrounding its use will be 
explored.  This chapter further describes the rationale for aminophylline use 
in children and outlines the potential of this work to improve asthma 
outcomes. 
1.2 Pathophysiology of Asthma  
1.2.1 Asthma Triggers 
Asthma is a heterogeneous disorder, characterised by chronic inflammation of 
the lower airways resulting in intermittent and reversible airways obstruction 
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[12]. Patients with asthma have a heightened responsiveness to stimuli that 
trigger little or no change in normal individuals. An exacerbation of asthma is 
a deterioration in symptom control that is sufficient to cause distress or risk to 
health [13]. Once an exacerbation has been initiated, inflammation and 
enhanced bronchial responsiveness result in airways obstruction. The clinical 
manifestations of an exacerbation include shortness of breath, wheezing, 
coughing and chest tightness.  
 
The precise pathophysiological processes underlying asthma are poorly 
understood and involve an array of cells, inflammatory mediators and nervous 
impulses. The composition of these mediators may vary between individuals 
and different types of asthma [14], resulting in a spectrum of severities, 
clinical features and responsiveness to treatment.  
 
Atopy is a genetically determined state of hypersensitivity towards 
environmental allergens, which predisposes individuals to asthma, eczema 
and allergic rhinitis. Atopy cannot provide a comprehensive explanation to all 
the clinical features of asthma, as it is not a unified disorder. However it is 
widely accepted that a dysregulated immune system plays a significant role in 
asthma pathogenesis.  
 
Atopic asthma exacerbations are initiated following contact between an 
antigen presenting cell, which uptakes and processes allergens, and a Type 2 
T helper cell (TH2). A Th2 weighted immune response is associated with the 
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promotion of IgE, eosinophils and mast cells [15]. The release of mediators 
from inflammatory cells provoke an immediate reaction that occurs within 
seconds, and a late response that starts four to eight hours initial contact with 
the antigen 
 
The immediate response follows the exposure of an IgE coated mast cell to 
an inhaled allergen. Chemical mediators such as leukotrienes, histamine, 
prostaglandins and platelet aggravating factors, as well as stimulation of sub-
epithelial vagal receptors, provoke reflex bronchoconstriction. These 
mechanisms contribute to narrowing of the airways, oedema and mucus 
secretion that result in immediate asthmatic symptoms [16,17]. 
 
Mast cells release cytokines, which recruit eosinophils, leukocytes and 
neutrophils. These cells amplify and sustain the inflammatory response 
without exposure to the triggering antigen. Further pro-inflammatory 
mediators are released including major basic protein, eosinophil cationic 
protein, eosinophil peroxidase and leukotrienes. These mediators further 
contribute to airways obstruction and cause tissue damage and inflammation [18]. 
 
The distinction between atopic asthma (triggered by allergens) and non-
atopic asthma (triggered by non immune stimuli) is helpful from the 
perspective of pathophysiology, however a significant overlap between the 
two phenotypes is seen in clinical practice [19,20]. Most childhood 
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exacerbations are triggered by viruses rather than allergens , and the precise 
inflammatory pathways in non-atopic asthma are not known, and may involve 
a defective response to respiratory viruses or sensitization to environmental 
irritants.  
 
The profile of potential triggers is vast and varies widely between individuals. 
Several pro-inflammatory pathways may interact contributing to the wide 
spectrum of clinical and pathological outcomes [21,22]. Asthma can be 
classified based on its triggers, though this system is not universally accepted 
(Table 1). 
Table 1. Triggers associated with asthma exacerbations and their effects. 
[20,23,24] 
Trigger Examples Effect Mechanism 
Viruses Rhinovirus, Respiratory 
syncytial virus, human 
metapneumovirus, influenza 
virus 
Enhanced 
lower airway 
damage 
Deficient 
interferon-beta 
response 
Bacteria Mycoplasma pneumoniae, 
Chlamydia pneumoniae 
Unknown Unknown 
Allergen Pollen (tree, weed and 
grass), Fungi, Indoor 
allergens, animal dander 
Enhanced 
eosinophil 
response 
Allergic 
sensitization 
Occupational Chemical exposure Unknown Unknown 
Irritants Airway pollutants, cigarette 
smoke 
Increased 
eosinophilic 
and/or 
neutrophilic 
bronchitis 
Sensitisation 
Psychological Severe life event, chronic 
stress 
Unknown Unknown 
Medicines Aspirin, beta blockers Severe 
bronchospasm 
Unknown 
Other Pregnancy Unknown Unknown 
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1.2.2 Pathobiology  
Regardless of the underlying triggers, the final common pathway of asthma is 
multicellular inflammation, enhanced bronchial responsiveness and airway 
obstruction [24]. This results a ventilation perfusion mismatch and impaired 
gas exchange. In severe asthma exacerbations, profound airways obstruction 
means that arterial oxygen and/or carbon dioxide cannot be maintained at 
levels required to meet the metabolic demands of the body [25]. 
Hypersecretion from submucosal glands can result in complete occlusion of 
the airway lumen by mucous plugs [26]. Acidosis may be caused by a failure 
to expel carbon dioxide (respiratory acidosis) or ventilatory muscle fatigue 
(metabolic acidosis).  Haemodynamic alterations due to intrapulmonary 
shunting, increased right ventricular afterload and negative intrapleural 
pressure may further worsen the ventilation/perfusion mismatch. Asthma 
exacerbations can be fatal due to exhaustion from the overwhelming work of 
breathing, combined with hypoxia and its complications leading to respiratory 
arrest [27]. 
 
1.3 Management of Asthma Exacerbations	  
1.3.1 General Principles 
Effective management of a childhood asthma exacerbation involves resolving 
symptoms, reversing airways obstruction, reducing inflammation and 
correcting physiological abnormalities [28,29]. Medicines can be used to relax 
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bronchial smooth muscle and reduce inflammation. This reverses airways 
obstruction and allows effective gas exchange.  
 
1.3.2 First line treatment  
The management of an acute exacerbation of asthma can be divided into first 
and second line treatments [30]. First line therapy comprises oxygen to 
correct hypoxaemia [31], and inhaled/nebulised β2 agonists or ipratropium 
bromide to provide bronchodilaton [32]. Inhaled medicines selectively treat 
the pulmonary system resulting in fewer systemic effects. Additional oral or 
intravenous steroids may be required for their anti-inflammatory effects [33]. 
There is good evidence to support first line asthma management, and a 
majority of children require no further treatment.  
 
There is a small subset of children with severe asthma who do not respond to 
first line therapy and require further treatment for an exacerbation. Drug 
delivery to the peripheral airways may be impeded by bronchospasm, mural 
inflammation and mucus impaction [34]. Patients in acute respiratory distress 
may not be able to generate the necessary flow rates for drug delivery due to 
fatigue of the respiratory muscles. These factors limit the efficacy of first line 
treatment, as inhaled medicines are unable to reach their site of action and 
provide therapeutic benefit.  
 
Intravenous medicines provide an alternative route of drug delivery for 
children suffering a severe exacerbation of asthma. Intravenous therapies 
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may be more effective at reversing asthma symptoms, but have the potential 
to cause serious adverse effects [35]. The decision to commence intravenous 
treatment must balance the need to prescribe an effective medicine, with the 
potential harms from adverse effects.  
 
1.3.3 Second Line Treatment  
Second line treatment of asthma exacerbations comprises three medicines: β2 
agonists (salbutamol), methylxanthines (aminophylline) and magnesium 
sulphate. There is a scarcity of relevant studies investigating the beneficial 
and harmful effects of intravenous therapy in children, and systematic review 
evidence does not demonstrate superior efficacy of one drug over another 
[36-39]. This lack of evidence is reflected in conflicting national and 
international guidelines [30,40-42]. Thus, intravenous treatment regimens 
vary throughout the United Kingdom and Ireland, and the choice of which 
drug to use depends on local guidelines, habit and clinician experience, rather 
than high quality evidence [43] (Table 2).  
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Table 2. Recommendations for the dosing of intravenous drugs used in the 
second line treatment of children suffering an exacerbation of asthma 
Intravenous 
therapy   
 
British Thoracic Society 
Guideline 
Recommendations 2014 
[44] (level of evidence) 
 
Doses used in 
the UK and 
Ireland [43] 
 
Salbutamol Consider early addition of a 
single bolus dose of 
intravenous salbutamol (15 
µg/kg over 10 min) in a severe 
asthma attack where the 
patient has not responded to 
initial inhaled therapy (1+) 
 
Bolus/load: 2–
15 mg/kg over 
5–40 min 
Infusion: 0.3–5 
mg/kg/ min  
 
Aminophylline Consider aminophylline for 
children with severe or life-
threatening asthma 
unresponsive to maximal doses 
of bronchodilators and steroids 
(2+) 
 
Bolus load: 10 
mg/kg– 200 mg 
(total) over 
30 min 
Infusion: 0.5–
1.0 mg/kg/ h  
 
Magnesium 
sulphate  
Magnesium sulphate is a safe 
treatment for acute asthma 
although its place in 
management is not yet fully 
established. (1+) 
 
Bolus: 5–54 
mg/kg over 20–
30 min 
Infusion: N/A  
 
1+ Well conducted meta-analyses, systematic reviews, or RCTs with a low risk 
of bias, 2+ Well conducted case control or cohort studies with a low risk of 
confounding or bias and a moderate probability that the relationship is causal  
 
 
The optimum use of intravenous therapy in childhood exacerbations of 
asthma requires more than simply the selection of the right drug. The dosage 
and monitoring strategies have important influences on the risk/benefit profile 
of many drugs, which influences an individual’s therapeutic response. Ethical 
and practical challenges in undertaking pharmacokinetic studies in paediatrics 
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mean many children are denied the benefit of optimum asthma treatment, or 
are harmed from unpredicted adverse effects [45]. As the ideal prescribing 
practices of intravenous therapies in childhood asthma are not known, various 
dosing and monitoring strategies are used in studies comparing treatments. 
This lack of clarity means available literature may mislead clinicians wishing to 
make evidence based decisions regarding asthma treatment. Only when the 
optimum prescribing practices of intravenous antiasthmatic drugs are known, 
can definitive randomised controlled trials be undertaken comparing different 
asthma drugs [43].  
 
1.4 Intravenous Aminophylline in Childhood Asthma 
Exacerbations 	  
1.4.1 Aminophylline in acute asthma  
Aminophylline is a mixture of theophylline and ethyldiamine. Theophylline is 
the active compound with anti-asthmatic properties, whilst ethyldiamine is an 
excipient, which confers greater solubility in water. 
 
The use of aminophylline in asthma increased during the 1970’s and 1980’s 
due to a better understanding of its pharmacokinetics and 
pharmacodynamics, improvements in serum measurement and the 
development of slow release preparations [46]. In the 21st century, the use of 
aminophylline in asthma exacerbations has largely been surpassed by inhaled 
medicines and systemic steroids. Aminophylline has a significant side effect 
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profile and is a relatively weak bronchodilator meaning it is only reserved for 
more severe exacerbations. An appreciation of the precise pharmacokinetic 
and pharmacodynamic properties of aminophylline is important in improving 
its prescribing practices.  
 
1.4.2 Mechanism of action 
Several mechanisms have been proposed for aminophylline, however its 
precise antiasthmatic mode of action is unknown. Bronchodilation, mediated 
by inhibition of phosphodiesterase (PDE) enzymes, is the most commonly 
accepted mechanism for the clinical efficacy of aminophylline.  
Phosphodiesterase enzymes degrade the phosphodiester bond within the 
second messenger molecules, cyclic adenosine monophosphate (cAMP) and 
cyclic guanosine monophosphate (cGMP). Inhibition of PDE causes an 
increase in the concentration of cAMP and cGMP within smooth muscle cells 
resulting in a reduction in cellular calcium concentrations, and activates 
protein kinase A. This increases the activity of myosin light-chain kinase and 
decreases the activity of myosin light chain phosphatase. Decreased 
intracellular calcium concentration and myosin light chain kinase activity leads 
to bronchial smooth muscle relaxation and reversal of airways obstruction (Fig 
1). Inhibition of PDE also accounts for the many side effects of aminophylline 
including headache, nausea, vomiting and increased acid secretion.  
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 Fig 1. Molecular mechanisms of action of bronchodilators. [47] 
 
VIP Vasoactive intestinal peptide, PGE2 Prostaglandin E2, AC adenylyl cyclase, 
Gs stimulatory G-protein, PKA protein kinase A, KCa calcium activated 
potassium channels, PI phosphinostide, MLCK myosin light chain kinase. 
 
Other mechanisms for the anti-asthmatic effect of aminophylline have been 
proposed. As knowledge of inflammatory pathways develops there is evidence 
that theophylline has anti-inflammatory and immunomodulatory effects [48]. 
Theophylline demonstrates adenosine receptor antagonism, which may 
further explain the beneficial and harmful effects of aminophylline [49]. 
Blockade of A2 receptors may prevent histamine release from mast cells and 
inhibit bronchoconstriction, whilst A1 antagonism is likely to account for its 
serious side effects such as seizures and cardiac arrhythmias. Other purported 
anti-inflammatory effects include raising the levels of interleukin-10 [50] 
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reducing the expression of inflammatory genes, and reversal of steroid 
resistance through activation of histone deacylases [51] (Box 1).   
Box 1. Proposed mechanisms of action of theophylline. [52] 
 	  	  
1.4.3 Pharmacokinetics  
The steady state concentration of aminophylline is when the overall intake of 
a drug is in a dynamic equilibrium with its elimination [53]. Once steady state 
has been achieved, serum levels of theophylline remain relatively constant 
and its therapeutic properties can be maximised (Fig 3). Aminophylline has a 
long half-life meaning it is eliminated from the body relatively slowly [54-56]. 
Serial administration of aminophylline could result in delayed therapeutic 
efficacy as it takes around five half lives to achieve steady state 
concentrations. In an acute exacerbation of asthma, it is important that the 
therapeutic effects of aminophylline occur rapidly to hasten recovery. 
However, dosing children too quickly may result in overdose, with the 
resulting toxic concentrations taking a long time to clear.  
Phosphodiesterase inhibition 
Adenosine receptor antagonism 
Inhibition of nuclear factor κBIncreasing Histone deacetylase 2 
via Inhibition of phosphoinositide 3-kinase- 𝛿  
Increasing IL-10 secretion 
Increasing Apoptosis of inflammatory cells (neutrophils, T cells)  	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 Fig 2. State concentration following serial admission of a medicine [57] 
 
The rationale for current prescribing practices of intravenous aminophylline is 
based on a purported correlation between drug concentrations in the blood 
and clinical efficacy [58]. Based on this assumption, there is a theoretical 
window of serum theophylline concentrations that provides optimum anti 
asthmatic action with minimal adverse effects. This therapeutic range of 
aminophylline is said to be narrow, meaning small differences in blood 
concentrations may lead to either therapeutic failure or increased likelihood of 
adverse drug reactions. Current guidelines recommend aiming for serum 
concentrations between 10-20mg/l [30,44].  
 
The plasma theophylline concentration resulting from a given dosage is 
relatively uncertain due to the high level of interindividual variation in 
theophylline clearance rates. As the correlation between dosage and serum 
concentration is poor, theophylline measurements in the blood are used as 
surrogate indicators of efficacy [59].  
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1.4.4 Therapeutic drug monitoring  
Aminophylline is subject to therapeutic drug monitoring (TDM) due to its 
narrow therapeutic range, significant adverse effect profile and unpredictable 
pharmacokinetics. Patients who treated with aminophylline receive blood 
tests, which are used to measure serum drug levels in a laboratory. These 
results are compared to a reference range, and subsequent dosages are 
adjusted allowing individualization of aminophylline dosage that reflects the 
child’s pharmacokinetics.  
 
Guidelines for prescribing aminophylline in children are complex. There are 
two separate algorithms based on whether a child takes a regular oral 
theophylline medication. Patients who do not take regular oral theophyllines 
receive a 5mg/kg loading dose and an infusion at a rate of 0.5mg/kg/hr to 
1.0mg/kg/hr depending on the age of the child. Oral preparations of 
theophylline such as Nuelin SA and Slo-Phyllin are prescribed for chronic 
asthma. When these children present to emergency departments requiring 
intravenous aminophylline, their serum theophylline concentrations are not 
known and a uniform loading dose in these patients may result in toxicity. 
These patients receive an aminophylline infusion on admission. Once their 
serum levels are confirmed, a decision is made on whether a top up loading 
dose is required. 
 
Once treatment with intravenous aminophylline has been initiated, TDM is 
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used to guide further dosage. Serum levels should be checked every 24 
hours, with infusion rates adjusted so that children maintain serum 
theophylline concentrations between 10-20mg/l (Fig 3).  
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Fig 3. Alder Hey guidelines for aminophylline dosage and monitoring  
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Monitoring blood theophylline levels in patients receiving aminophylline 
represents an early effort to tailor aminophylline dosage to an individual’s 
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pharmacokinetics. Infusion rates are altered to keep serum theophylline 
concentrations within its therapeutic range. The assumption that a serum 
theophylline concentration between 10-20mg/l represents the maximum 
efficacy and safety of aminophylline is based on improvements in spirometry 
measurements in adults who are not acutely unwell [60-62]. Adults are 
inappropriate study participants on which to base paediatric treatment, and 
one wouldn’t measure spirometry in acute exacerbations to establish a serum 
theophylline concentration that represents the maximum efficacy and safety 
of the drug.  
 
1.4.5 Cytochrome P450 Enzymes  
The cytochromes P450 (CYPs) are a superfamily of haeme containing 
enzymes responsible for the demethylation of theophylline to 1-
methylxanthine and 3-methylxanthine. The removal of the methyl group from 
theophylline renders it pharmacologically inactive. At theophylline 
concentrations used in clinical practice, CYP1A2 is the enzyme responsible for 
drug metabolism. At very high theophylline concentrations, the CYP2E1 
enzyme has an additional role in demethylation (Fig 4).   
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Fig 4. Metabolic pathways of theophylline in humans [63] 
 
 
The activity of CYPs is influenced by a unique combination of genetic and 
environmental factors that alter its expression. Factors that increase the 
expression of CYP1A2 are known as inducers, and include smoking, caffeine 
and rifampicin. Under these circumstances, clearance rates of theophylline 
are increased, resulting in lower serum concentrations and potential 
therapeutic failure. Conversely, inhibitors of CYP1A2 such as the oral 
contraceptive pill, quinolones and isoniazid, may decrease theophylline 
clearance leading to toxicity [64]. Genetic factors such as the influence of 
polymorphisms of the gene that codes for the CYP1A2 enzyme may further 
influence aminophylline disposition.  
 
The optimum dose of aminophylline may be specific to an individual’s 
pharmacokinetics, and individualization aminophylline therapy could maximise 
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the efficacy and safety of the drug. As the factors underlying interindividual 
variation are not known, initial dosage of aminophylline is low to circumvent 
side effects, with subsequent doses titrated to the individual demands of 
patients. This process is slow and may not represent the best use of 
intravenous aminophylline. These factors mean patient response to 
aminophylline is highly variable, and there may be scope to target therapies 
to specific groups of patients based on prior knowledge of their clinical and 
genetic profiles. 
 
To improve asthma outcomes in children, it is important to determine 
whether patients experience important benefits from a particular dose or 
monitoring strategy of aminophylline [65]. The selection of appropriate 
outcomes is crucial when assessing drug dosage and monitoring. Since the 
establishment of the therapeutic range in the 1960’s and 1970’s, there has 
been a greater understanding of the importance of measuring clinically 
relevant outcomes when assessing the efficacy of an intervention in acute 
asthma. A set of core outcomes has been developed in conjunction with 
patients, families and healthcare professionals, in an effort to improve the 
clinical relevance of studies [66]. However, there is no specific outcome set 
for acute asthma. An investigation into whether serum levels between 10-
20mg/l correlate with a true improvement of children suffering an acute 
exacerbation of asthma is required. This will be the first step in stratifying 
aminophylline therapy.  
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1.4.6 Interindividual variation	  
Asthma is a common condition, affecting a diverse population encompassing 
many ages, ethnicities and severities. Increasing awareness of the 
heterogeneity of asthma may help to explain the variability in response to 
treatment [67,68]. The identification of responders and non-responders for a 
given medicine may be a key step in maximising the efficacy and safety of 
current asthma therapies. The sources of variability in aminophylline response 
are multifactorial and may be determined by genetic, environmental and host 
factors (Box 2).  
  
Box 2. Factors that may influence treatment response to aminophylline  
 
 
Personalised medicine involves tailoring treatment to meet the needs of 
individual patients based on their predicted response to a drug [69]. 
Personalised medicine relies on an understanding of the precise mechanisms 
which determine responsiveness to treatment. This requires the consideration 
of many factors that may influence how patients respond to medicines, from 
the genetic, molecular and cellular to the environmental. The goal of 
Genetics 
Age 
Developmental status 
Severity of baseline inflammation 
Remodelling from chronic disease 
Sensitivity towards environmental triggers 
Exposure to environmental triggers 
Interactions with other drugs 
Adherence to asthma therapy 
Drug allergies  
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personalised asthma therapy is steering selected patients to the right drug, at 
the right dose at the right time to maximise the risk benefit ratio of 
interventions. 
 
1.4.7 Age specific doses 
Age is a well-recognized factor in determining the optimum treatment for 
acute asthma. The established management for adults suffering an acute 
exacerbation may be inappropriate in children, and separate medicines and 
doses may need to be recommended [30]. Ethical and practical limitations of 
conducting drug research in children means the specific pharmacokinetics and 
pharmacodynamics of many drugs are poorly understood in paediatrics. Age 
and weight specific doses are already recommended when aminophylline is 
used in acute asthma. Children under 11 receive higher relative doses per 
unit of body weight to account for their observed faster clearance rates [11]. 
 
1.4.8 Pharmacogenomics and Pharmacogenetics  
Pharmacogenomics is the study of all the genes in the genome that may 
determine drug response at a cellular, individual or population level response 
[70]. In asthma, this encompasses the study of asthma genes associated with 
susceptibility, and genes encoding for drug metabolism enzymes, 
transporters, receptors and transduction pathways.  Pharmacogenetics is a 
more specific term, usually referring to the study of specific variations in DNA 
sequence in relation to drug [67]. Pharmacogenomics and pharmacogenetics 
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may be important tools in stratifying asthma therapy. It is hoped that 
combining genetic information with pharmacotherapeutic data will enable the 
development of tailored regimens that maximize efficacy and minimize 
adverse events in treating acute exacerbations of asthma.  
 
The number of potential determinants of response to therapy is vast. If 
tailored asthma therapy is to become a reality, it requires a holistic 
investigation into the determinants of interindividual variability of a specific 
drug. If such an association between a genetic/environmental factor and 
treatment response is found, there is potential to stratify intravenous 
aminophylline for children suffering an acute exacerbation of asthma.  
 
1.5 Aims and Objectives  
This work aims to improve the evidence base for aminophylline dosage and 
monitoring for children suffering an acute exacerbation of asthma. 
 
Chapter two is aims to systematically review current evidence for the 
optimum therapeutic range of intravenous aminophylline in children. This is 
the first systematic review investigating the optimum therapeutic range of a 
drug and this chapter explores the methodological challenges of conducting 
studies of this type.  
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Chapter three is another systematic review, which aims to investigate the 
evidence base of the current dosing recommendations of aminophylline 
(5mg/kg bolus followed by an infusion between 0.5-1.0mg/kg/hr). 
 
Chapter four aims to assess adherence aminophylline prescribing guidelines, 
and describe the pharmacokinetics of aminophylline in children suffering an 
acute exacerbation of asthma. This is an audit of current prescribing practices 
of at Alder Hey children’s hospital, and compares the outcomes of children 
who achieve ‘therapeutic’ vs ‘non therapeutic’ serum levels.   
 
Chapter five describes the development of a pilot study investigating the 
pharmacogenetics of aminophylline. This prospective cohort study aims to 
investigate the role of CYP1A2 polymorphisms of aminophylline disposition, 
and clinical outcomes of children.   
 
Chapter six discusses the findings from these works and their relevance for 
clinical practice.  
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Chapter 2: The Evidence for 
Achieving Intravenous 
Theophylline Levels between 
10-20mg/L in Children 
Suffering an Acute 
Exacerbation of Asthma: A 
Systematic Review 
 
2.1 Background 
2.1.1 Therapeutic drug monitoring evidence  
Therapeutic drug monitoring (TDM) is predicated on a definable relationship 
between clinical outcomes and serum drug concentrations [58]. To maximise 
the efficacy and safety of intravenous aminophylline, TDM practices should be 
based on evidence of clinical improvement. Target theophylline 
concentrations between 10-20mg/l are the most widely accepted [30,44], 
however the evidence for this recommendation is unclear.  
 
The therapeutic range of intravenous aminophylline is based on 
improvements in spirometry in adults. Although the relationship between 
serum levels above 10mg/l and improving FEV1 and is consistent across 
studies [61,62,71,72], this is a poor evidence base on which to guide therapy 
for children in the acute setting (Chapter 1). A small number of studies report 
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an increase in adverse effects above 20mg/l	  [73-75]. An investigation into the 
relationship between serum theophylline concentrations and clinical 
improvement of asthma exacerbations is required to improve prescribing 
practices.  
 
Systematic reviews condense large amounts of heterogeneous information 
into a manageable format that can inform clinical decisions. They are a key 
component of the evidence based medicine movement and provide the best 
possible estimate of any true effect.  
 
2.1.2 Aim 
This chapter aims to review the evidence for the current therapeutic range of 
intravenous aminophylline (10-20mg/l). It outlines the basic principles of 
systematic reviews, and explores the methodological considerations when 
undertaking a review of this type. 
2.2 Methods 
2.2.1 Study design 
A systematic review of studies investigating the use of intravenous 
theophyllines in acute asthma in children that report both relevant clinical 
outcomes and theophylline levels.  
 
2.2.2 Included Studies  
Included studies were parallel and crossover randomized controlled trials 
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(RCTs) comparing two or more therapeutic ranges for intravenous 
theophyllines in children and adolescents (aged 19 or younger) with acute 
asthma. RCTs comparing intravenous theophyllines with placebo were also 
included, if a measure of serum theophylline levels was reported for the two 
treatment groups, retrospective or prospective observational studies were 
also eligible if they reported results for both clinical outcomes and therapeutic 
levels measured. 
Studies including adults (20 years and older) and children were excluded, 
unless the paediatric data were reported separately. Children have differing 
pharmacokinetic and pharmacodynamic properties when compared with 
adults [76-78]. These differences will affect the safety and efficacy profile of 
intravenous aminophylline, and therefore its optimum therapeutic range in 
asthma. Studies utilizing aminophylline for an indication other than asthma 
were excluded (e.g. neonatal apnoea and tuberculosis), as measures of drug 
efficacy are dependent on its indication. As acute versus chronic indications 
have different risk benefit rations, this study focused on acute exacerbations 
only.  
 
2.2.3 Outcomes  
If the results of the systematic review are to identify appropriate therapeutic 
ranges, selected outcomes must reflect beneficial and harmful effects of the 
drug, which are relevant to clinical practice in context of the population of 
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interest. Outcomes must be selected prior to literature searching to prevent 
over reliance on inappropriate outcomes that may not be relevant [79]. 
 
Although spirometry provides an objective measurement, it is an imperfect 
marker of asthma improvement. Spirometry is effort dependent frequently 
inaccurate in the very young or ill, and correlates poorly with asthma 
symptoms [80-82]. Since therapeutic ranges were established in the 1960’s, 
the importance of selection outcomes that reflect clinical improvement of 
asthma exacerbations has been recognized [65,66,83]. This systematic review 
uses a core outcome set that has been developed in collaboration with 
clinicians, patients and their families to ensure that the measured outcomes 
translate into real world improvement [66].  
  
The pre-specified primary outcomes were i) time until resolution of symptoms 
ii) need for mechanical ventilation, and iii) mortality. Secondary outcomes 
were i) days until discharge criteria are met ii) actual discharge from hospital 
and iii) adverse effects as defined and reported by authors. Forced expiratory 
volume in one second was used to assess the incidental relationship between 
serum concentrations and spirometry. Studies must have reported at least 
one outcome to meet our inclusion criteria.  
 
2.2.4 Identification of studies 
Few primary studies directly investigate therapeutic ranges [84,85] and a 
range of scenarios were anticipated prior to searching. Several levels of study 
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design were considered, which the available evidence to be systematically 
graded. This avoided placing inappropriate weight on studies that are 
methodologically less robust when formulating conclusions.  
 
The optimal scenario was a systematic review of RCTs comparing two or 
more therapeutic ranges of intravenous aminophylline. RCTs were considered 
the highest grade of evidence as randomization minimises selection bias, and 
accounts for unknown confounding variables.  
 
The suboptimal scenario incorporated either observational data or indirect 
comparisons between clinical trials such as RCTs comparing aminophylline to 
placebo/other treatment. Observational data may be obtained from cohort 
studies, case-control studies, or case series. Indirect evidence may be gained 
from identifying RCTs that have compared the drug against a common 
comparator (likely placebo), and then analysing whether studies, in which a 
higher serum concentration was achieved, demonstrated superior outcomes. 
 
Electronic search engines were used, which include several databases to 
identify studies for this review. Included databases included: medline 
(complete), Excerpta Medical database (EMBASE), PubMed Central, 
Compendex, World Textile Index, Fluidex, Geobase, Biobase, CINAHL and 
PSYCHinfo. Unpublished data was identified by searching the Cochrane 
Register of Controlled Trials (CENTRAL) to avoid the problems of publication 
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bias. CENTRAL provides additional evidence that may not be included in other 
databases [86]. 
 
The following terms were used in the literature search in September 2015 
with no date or language restrictions: 
 
((aminophylline  OR  xanthine OR  phyllocontin  OR  theophylline  OR  pde4 
inhibitor  OR  phosphodiesterase 4 inhibitor  OR  caffeine) and 
(intravenous  OR  IV OR  parenteral) AND (acute asthma OR 
asthmaticus  OR  severe asthma  OR  "hospital*ed"  OR asthma attack") AND 
(child*  OR  adolescen*  OR  infan*  OR  p*ediatric))   
 
Brand names of aminophylline were included, as well as the class of drugs to 
which it belongs (pde4 inhibitor). As acute exacerbations are frequently 
described using variable terminology [27], terms were included that could 
capture studies describing the following phenomenon: acute asthma, asthma 
exacerbations, status asthmaticus, asthma attacks. Numerous paediatric 
search terms were used as there is no consensus on the strategy for 
identifying studies relevant to children [87]. The search term was not 
included “therapeutic range” as many relevant studies may not include this 
term in their keywords or abstract and its inclusion would result in an overly 
specific search strategy, and the potential exclusion of relevant studies.  
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One reviewer (LC) screened all abstracts and a second reviewer (IS or DH) 
checked the eligibility of abstracts after initial screening, and full studies 
included in the review. Reference lists were screened for other eligible 
studies.  
 
2.2.5 Assessment of Quality and Risk of Bias 
An assessment of quality allows the reviewers to present the degree to which 
the results in the available literature are valid and robust, and whether 
conclusions that impact on clinical practice should be made. There is no 
appraisal tool for systematic reviews investigating the optimum therapeutic 
range of a drug. Our methods for quality assessment must encompass the 
several scenarios anticipated based on the available evidence. As many 
different study designs may be included in this review, numerous appraisal 
tools were considered (Table 3). 
 
Table 3. Tools used for appraisal of quality which may be used in this review  
Study Design Available Tools 
Systematic 
Review 
Preferred Reporting Items for Systematic Reviews and 
Meta Analyses (PRISMA) - for reporting 
 
Randomized 
controlled trials 
Critical Appraisal Skills Programme (CASP) – Reporting 
and Conduct 
 
Cohort studies Critical Appraisal Skills Programme (CASP) – Reporting 
and Conduct 
Case control 
studies 
CASP tool for conduct and reporting 
Case reports CARE tool for reporting  
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 There are specific considerations of quality assessment when undertaking a 
systematic review of therapeutic ranges, which may not be included in quality 
assessment tools.  
 
The measurement of drug concentrations in serum provides a snapshot of the 
dynamic process of drug clearance. The timing of measurement therefore 
influences the results of therapeutic drug monitoring [88]. Drug levels should 
be measured at the same time across participants to give an accurate 
representation of drug levels achieved.  
 
Deciding the upper limit of a therapeutic range requires relevant data on the 
harmful effects of drugs. Ad hoc measurement of adverse effects carries the 
risk of selective outcome reporting [89], which could misinform the upper 
limit of a therapeutic range.  These factors were taken into consideration 
when assessing quality. 
 
The Cochrane risk of bias tool was used to assess aspects of trial design, 
conduct, analysis and reporting that would cause results to differ from the 
true values [79]. This tool would be used to assess all included RCTs in this 
study.  
 
2.2.6 Data extraction and analysis  
From each study we identified the theophylline levels achieved in the research 
participants (and when these were measured) and, if stated, the desired 
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target range. We extracted data around our selected outcomes, at whichever 
timepoints they were reported. We also recorded the age range of 
participants. From RCTs, exclusion criteria, control medication, concomitant 
medication and statistical significance of results were also noted. 
 
Systematic reviews require the methods of statistical analysis to be devised 
prior to searching. As the availability of relevant evidence was not known, 
several scenarios were anticipated. In our optimal scenario, a meta-analysis 
was planned if numerous studies that investigate the relationship between 
serum drug concentrations were identified. This would allow a quantitative 
summary of the relationship between serum drug concentration and clinical 
efficacy. A descriptive analysis was planned if quantitative data synthesis was 
not possible.   
 
2.3 Results 
2.3.1 Included Studies  
A total of 506 studies were found using the search criteria, with 22 full text 
articles screened for eligibility. We excluded 10 full text articles (appendix) 
with the remaining 12 articles included in the review (Fig 5).   
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Fig 5. Search Results of the systematic review investigating the optimum 
therapeutic range if intravenous aminophylline    
 
 
We found no RCTs comparing different therapeutic ranges of aminophylline 
and we used indirect data for our analysis. We included ten RCTs comparing 
theophylline with placebo, and two retrospective observational studies. There 
were insufficient studies comparing aminophylline to a comparator drug (eg 
salbutamol or magnesium sulphate) for data analysis comparing, hence only 
RCTs comparing aminophylline to placebo were included. 
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2.3.2 Quality of included studies  
Of the ten randomized controlled trials, two studies gave no data on adverse 
effects [90,91], two studies reported side effects unsystematically [92,93] and 
six reported adverse effects thoroughly using prospective methods clearly 
outlined in the methodology [94-98]. 
 
Each study was assessed for its risk of selection bias, performance bias, 
detection bias, attrition bias and reporting bias. The results of the Cochrane 
risk of bias assessments are shown in Fig 6. Three studies were classed at 
high risk of attrition bias, one at high risk of reporting bias with respect to 
symptom scores, and three at high risk of reporting bias of adverse 
outcomes. The other domains of bias were classified as low or unclear risk in 
most studies. 
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Fig 6. Assessment or Risk of Bias of included studies in a systematic 
review investigating the optimum therapeutic range of intravenous 
aminophylline  
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The CASP assessments conducted on the two observational studies are 
presented in Table 4. 
 
Table 4 Assessment of quality in observational studies.  
 Dalabih 2014 Fox 1982 
Clearly focused issue ê ê 
Acceptable recruitment ê ê 
Adequate exposure measurement  ê ê 
Adequate outcome measurement  ê ê 
confounding factors identified é é 
Complete follow up? é é 
Result precision ? ? 
Believable results ê ê 
Applicable to local population ê ê 
Consistent with other evidence ? ê 
ê low quality domain, é high quality domain, ? unclear quality domain 
2.3.3 Study Characteristics   
The theophylline levels reached, primary outcomes and secondary outcomes 
are shown in Tables 5-7. Studies were ranked from lowest theophylline level 
achieved to highest, this process was limited due to inconsistent reporting.  
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Table 5. Characteristics of included RCTs 
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2.3.4 Theophylline levels 
For the 10 RCTs, six gave an optimal therapeutic range for theophylline: three 
studies aimed for serum concentrations between 10 and 20mg/l [90,94,96] 
one study of 15mg/l [98], one between 12-17mg/l [99] and one between 12-
20mg/l [92]. Of the observational studies, one defined target therapeutic 
levels as 10mg/l or greater [100] and one as 10-20mg/l [101].  
 
There was non-uniformity in the timing of theophylline level measurement. Of 
the randomized controlled trials, three measured serum levels 30 minutes 
after completion of the loading dose [90,97,98], three after one hour of 
completion of the loading dose [94,95,99], and one six hours after completion 
of loading dose [92]. The timing of serum measurement was not reported in 
one RCT and neither observational study [91,100,101]. Serum levels were 
measured in all participants receiving theophylline, except in one study, 
where only 17% of those in the intervention group had serum theophylline 
levels measured [91].  
 
There was heterogeneity between studies in the way in which theophylline 
levels were reported. Five studies presented the mean theophylline level 
achieved [91,92,96,97,100], three gave the proportion of research 
participants who were below/above the target range [95,100,101] and four 
gave the range of theophylline levels achieved [90,93,94,98].  
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2.3.5 Primary Outcomes 
1) Time until resolution of symptoms. Of the ten RCTs, two reported time 
until resolution of symptoms as an outcome [92,99], four measured change in 
asthma score over a given time [90,94,96,98], and four did not measure 
symptoms. Various symptom scores were used (Table 4).  
 
There appeared to be no difference in the magnitude of results when 
comparing levels of serum theophylline measured in participants. One RCT 
demonstrated that symptom improvement was quicker in those receiving 
theophylline compared with placebo (18.6±2.7h vs 31.1±4.5h [p<0.05], 
mean serum theophylline levels 11.2mg/l) [99] but this was not replicated in 
another study in which similar serum theophylline levels were reported 
(30.4±16.8h vs 27.0±10.3h [p=0.51], mean serum theophylline level 
13.1mg/l) [92]. No studies demonstrated a statistically significant 
improvement in symptoms after 2, 6, 12, 24, 48 and 36 hours at any serum 
theophylline level [90,94,96-98]. 
 
One retrospective study measured time until symptom improvement and 
found that this appeared to be longer after treatment with aminophylline 
(hazard ratio 0.359, p<0.001). The authors also note that this was 
significantly more prolonged in those with levels >10mg/l compared to those 
who are subtherapeutic (hazard ratio 0.403 p=0.0085) [100].  
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2) Need for mechanical ventilation. No studies compared the effect of IV 
aminophylline against placebo, in non-intubated children, on the subsequent 
need for mechanical ventilation.  
 
3) Mortality. There were no reported deaths in any study. 
2.3.6 Secondary outcomes 
1) Date until discharge criteria are met. One study reported time until 
children were ready for discharge home and found no significant difference 
between theophylline and placebo (27.0±10.3 hours vs 30.4±16.8 hours 
[p>0.05] mean theophylline level 13.1mg/l) [92]. Another study measured 
time to meet discharge criteria from the intensive care unit, but not time until 
discharge home. The study reported a statistically significant difference in 
favour of aminophylline (29.8±4.9h vs 36.4±5.5h [p<0.05]. Mean daily 
theophylline level 14.5±0.7 mg/L, target theophylline levels 12-17mg/l) [99].  
 
2) Actual discharge. Four studies recorded length of time in hospital as an 
outcome. One study, in which mean theophylline levels were 7.2mg/l [91] 
and one study with mean levels of 12.3mg/l [95] demonstrated no statistically 
significant difference in length of hospital stay when compared to placebo. 
One trial demonstrated a significant improvement in length of stay in critical 
care in the aminophylline group compared with placebo (3.9±0.3 days versus 
8.8±1.5 days in placebo [p<0.05] mean serum theophylline level 11.2mg/l), 
but not in discharge home (8.3±1.5 days versus 13.0±1.0 days [p>0.05] 
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mean serum theophylline level 11.2mg/l). This study demonstrated a 
significantly shorter length of stay in critical care in the very small subset of 
intubated patients receiving aminophylline compared to those receiving 
placebo [99]. 
 
One retrospective study found that length of stay in critical care was longer 
for subjects receiving aminophylline (hazard ratio 0.396, [p=0.001], 63% of 
participants >10mg/l) but does not follow up patients until discharge home. 
Of those receiving aminophylline, those found to have levels >10mg/l had a 
longer stay in the intensive care unit compared to those who with levels 
<10mg/l [100]. Another retrospective study reported the mean length of stay 
of hospital for patients receiving aminophylline was 3.25 days, however no 
comparison is made between those achieving different serum theophylline 
levels [101].  
 
3) Adverse effects. Eight RCTs reported adverse effects. Three studies 
demonstrate statistically significantly higher rates of adverse effects in those 
receiving intravenous theophyllines compared to placebo [95-97] whilst 
another study showed no significant difference [94]. In the few research 
participants with supratherapeutic theophylline levels (>20 mg/l) there did 
not appear to be an increased risk of side effects. One retrospective study 
reported no adverse effects in any of its supratherapeutic patients [101], and 
one study linked adverse effects to an individual participant who experienced 
nausea and abdominal pain with levels of 23mg/l [97]. 
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4) Spirometry. Three studies reported FEV1 as an outcome. Two studies 
demonstrated significant improvements in FEV1 in the theophylline group 
compared to placebo (22.5 vs 13.1 [p=0.029], serum level of participants 10-
20mg/l) [94] (89 vs 62 [p<0.001], serum level of participants 5-15mg/l) [93] 
whilst another study with theophylline levels between 10-20mg/l 
demonstrated no statistically significant difference in FEV1 [98]. In other 
studies, a large proportion of participants were unable or unwilling to perform 
spirometry. 
 
2.4 Discussion  
There is no evidence to suggest that 10-20 mg/l of theophylline is the optimal 
target serum range in children with severe acute asthma. Across studies 
comparing aminophylline to placebo there appears to be no difference in 
symptom resolution between children with serum theophylline concentrations 
between 10-20mg/l, and those under 10mg/l. There is no evidence to suggest 
serum concentrations within the therapeutic range reduce the need for 
mechanical ventilation or mortality. There is weak evidence to suggest that 
levels over 20 mg/l are associated with an increase in abdominal pain, nausea 
and vomiting.  
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The principles of TDM are based upon a correlation between serum drug 
concentrations and clinical outcomes. This review demonstrates that there is 
an unclear relationship between serum levels and either clinical efficacy or 
development of adverse effects. Until there is clear evidence that the 
beneficial serum level of theophylline lies within a certain range, rigorous 
evaluation of clinical progress and adverse drug effects should be used to 
guide therapy rather than laboratory investigations.  
 
Data from one study suggests that a 5mg/kg loading dose would leave one 
third of children below 10mg/l, and none above 20mg/l [102]. Routine 
measurement of serum theophylline levels in children suffering acute asthma 
who have received standard loading doses of aminophylline to achieve serum 
concentrations in the 10-20mg/l range is therefore unlikely to result in any 
clinical benefit or reduction in adverse effects. However measurement of 
serum theophylline in childhood acute severe asthma may still retain utility in 
the assessment of patients in whom there is concern about overdose.  
 
As we were unable to identify any RCTs directly comparing target ranges of 
theophylline, our analyses incorporate indirect observational comparison 
across studies. For an evidence based therapeutic range to be determined, 
there is a need for RCTs comparing ranges and measuring important clinical 
outcomes, to determine the optimal dose in children. 
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Many included studies measured outcomes that are poor reflections of patient 
improvement, and there was poor reporting of the results of TDM across 
studies [66]. Furthermore, our included studies span a 43 year time period 
and changes clinical practice, administration of IV aminophylline and the 
selection of outcomes present further challenges when comparing results. All 
of these issues contribute to data heterogeneity.  Meta-analysis was 
considered but is unlikely to provide further insight into the optimum 
therapeutic range of aminophylline. 
 
Research in children presents specific challenges such as potential difficulty in 
reporting subjective side effects and reluctance to take blood samples, so 
monitoring of adverse effects may be difficult. We agree with the need for 
consistent reporting of adverse effects in clinical trials [89]. A core outcome 
set is needed to measure and report outcomes in all trials. This should be 
developed using rigorous consensus methodology [66] and would help 
interpretation of studies, enable synthesis across trials, and reduce reporting 
bias [65]. 
 
2.5 Conclusion 
There is no evidence that theophylline levels above 10mg/l compared with 
levels below 10mg/l are associated with improvement in children with severe 
acute asthma, nor that levels below 20mg/l are associated with fewer adverse 
effects than higher levels. Even if theophylline levels are measured, we 
recommend that clinicians should be guided by clinical improvement, and be 
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vigilant to adverse effects, rather than simply titrate the dose according to 
serum levels. Randomized controlled trial evidence comparing two therapeutic 
ranges may provide further information on the optimum serum concentrations 
of intravenous aminophylline. These should measure and report a 
standardized core set of validated outcome measures reflecting both benefits 
and harms.  
 
2.6 Summary 
The optimum monitoring practices of intravenous aminophylline are not 
known. This chapter aimed to assess whether serum theophylline levels 
between 10-20mg/l are associated with superior clinical asthma outcomes in 
children. A systematic review found a poor evidence base for the current 
therapeutic range. As the results of TDM are factored into aminophylline 
dosage, alternative prescribing practices may benefit children suffering an 
exacerbation of asthma. An enquiry into the optimum dosing regimen of 
aminophylline is an important stage in assessing the evidence for current 
aminophylline recommendations.   
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Chapter 3: A Systematic 
Review of Aminophylline 
Dosage  
 
3.1 Background 	  
3.1.1 Safe Prescribing  
Aminophylline prescribing practices should reflect the maximum safety and 
efficacy profile of the drug. Inappropriate dosage can result in toxicity from 
an overdose, or therapeutic failure if dosage is too small. This may prolong an 
acute exacerbation of asthma resulting in significant harm to children. When 
prescribing aminophylline to children, serum theophylline concentrations are 
incorporated into dosage calculations [30,44]. As serum theophylline levels 
were shown to be a poor predictor of efficacy of safety and efficacy in 
Chapter 2, an alternative dosing strategy may help maximize the benefit of 
intravenous aminophylline.  
 
Safe and effective prescribing of aminophylline requires an understanding of 
its pharmacological properties. Cardiac arrhythmias and seizures are 
potentially fatal consequences from aminophylline overdose [73-75], whilst 
other adverse effects such as nausea and vomiting are extremely distressing 
in the context of an acute exacerbation of asthma. Interindividual variation in 
clearance rates mean that a dose that is toxic in one patient may not provide 
adequate treatment in another. Safe dosing is further complicated its 
	   62 
purported narrow therapeutic range (Chapter 1).  
 
3.1.2 Dosage Calculations  
A loading dose is an initial higher dose of a drug that may be given at the 
beginning of a course of treatment to rapidly achieve therapeutic levels [103]. 
The half-life of aminophylline is long and treatment may be commenced with 
a loading dose to hasten its anti-asthmatic action. Once the desired serum 
levels have been achieved following loading, a maintenance infusion is 
administered. This is a lower dose of the drug intended to maintain 
aminophylline serum concentrations within the therapeutic range. Once 
steady state has been achieved, the rate of drug administration should be 
equal to elimination to keep serum concentrations constant. Not all children 
receive loading doses, such as those who take oral theophylline regularly 
(Chapter 1). Calculating aminophylline doses aiming for a therapeutic level 
requires knowledge of aminophylline disposition the optimal therapeutic level 
in children suffering an exacerbation of asthma (Fig 7).  
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Fig 7. Dosage calculations for intravenous aminophylline  
 𝐿𝑜𝑎𝑑𝑖𝑛𝑔  𝑑𝑜𝑠𝑒 =   𝐶!𝑉!𝐹𝑆  
Cp = Desired serum concentration 
of the drug 
Vd = Volume distribution of the 
drug 
F = Bioavailability 
S = Salt factor 
 
𝑀𝑎𝑖𝑛𝑡𝑒𝑛𝑎𝑛𝑐𝑒  𝑑𝑜𝑠𝑒 = 𝐶!𝐶𝐿𝐹  
Cp = Desired serum concentration 
of the drug 
CL = Clearance of the drug in body 
(L/h) 
F = Bioavailability 
Volume distribution: the theoretical volume that would be necessary to contain the total amount of an 
administered drug at the same concentration that it is observed in the blood plasma 
Bioavailability: the fraction of an administered dose of unchanged drug that reaches the systemic 
circulation 
Salt factor: the fraction of the administered dose, which may be in the form of an ester or salt, that is 
the active drug. 
 
Data on the optimum loading dose of aminophylline to use in children are 
conflicting and inconsistent. A loading dose of 5.6mg/kg has been calculated 
based on pharmacokinetic data of ten children aged between 1-4 years 
designed to achieve a concentration of 10mg/l [104]. In practice, a loading 
dose of 5mg/kg has been shown to be ineffective at achieving levels between 
10-20mg/l in around 30% of children [102]. A higher loading dose of 6mg/kg 
has been shown to achieve serum theophylline levels between 10-20mg/l in 
all children (n=11) [105], however this is inconsistent with more recent data 
[106]. These represent an early rationale for drug doses, but are 
underpowered and unable to account for the differing pharmacokinetic 
parameters across children of different ages.  
 
A lack of evidence is also seen in the recommended doses for maintenance 
doses of aminophylline. The rate of administration should equal the rate of 
elimination, however this is highly variable in a population. As younger 
children are purported to eliminate theophylline at a faster rate than older 
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children and adults [11], those under 12 receive infusion rates of doses of 
1mg/kg/hr, compared with 0.5mg/kg/hr in children over 12. To account for 
the individual variation in clearance rates, infusion are then adjusted based on 
the results of therapeutic drug monitoring. There is little data to suggest that 
children receiving aminophylline maintenance infusions achieve constant 
theophylline serum concentrations, or if these adjustments based on age 
represent the optimal dose of aminophylline.  
 
Chapter 2 did not show clear serum concentration at which aminophylline is 
most effective and pharmacokinetic studies alone would not be unable to 
guide optimum dosage. Instead, understanding the relationship between dose 
and outcome is required. 
 
3.1.3 Aim 
This chapter aims to investigate the correlation between aminophylline doses 
and clinically relevant outcomes. 
3.2 Methods	  
3.2.1 Study Design 
We conducted a systematic review of studies utilizing intravenous 
theophyllines in the management of asthma exacerbations in children in order 
to evaluate the optimum dosing strategy of intravenous aminophylline.  
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3.2.2 Included Studies 
The lack of primary research investigating the optimum dosages of drugs in 
children has been recognised [107]. Similar to the review question in Chapter 
2, the practical and ethical challenges faced when investigating aminophylline 
use in children means our methodology must account for the high probability 
of few primary studies directly investigating dosage. Therefore, we used a 
systematic review technique that anticipates various study designs, similar to 
the previous chapter. This systematic review technique has been used to 
assess the dosage of methotrexate [108]. We decided a priori that the most 
relevant study type would be a comparison of randomised controlled trials 
(RCTs) comparing different dosing strategies and measuring clinically relevant 
outcomes, but we would also include RCTs evaluating the efficacy of 
intravenous theophyllines compared with placebo or other treatment, with 
subsequent analyses performed for each comparator drug, and observational 
studies. 
 
We included studies that investigate the efficacy of intravenous theophyllines 
in children suffering an exacerbation of asthma if the dosing regimen was 
reported. We excluded studies performed in adults, those utilizing 
theophyllines for indications other than asthma or studies using non-
intravenous routes.  
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3.2.3 Outcomes  
Our selected outcomes were the same as those in Chapter 2. Primary 
outcomes were i) time until resolution of symptoms, ii) need for mechanical 
ventilation, and iii) mortality. Secondary outcomes were i) the number of days 
until discharge criteria are met, ii) number of days until actual discharge from 
hospital and iii) adverse effects as defined and reported by authors. 
 
3.2.4 Identification of studies   
The following search strategy was used to search MEDLINE, CINAHL, The 
Cochrane Central Register of Controlled Trials, and Web of Science in March 
2016 with no date or language restrictions: 
 
asthma*  AND  ( emerg*  OR  acute  OR  severe*  OR  intensive*  OR  exacer
bation  OR  critical  OR  refractory  OR  hospitali*ed  OR  attack  OR  status ) 
 AND  ( aminophylline*  OR  intravenous  theophylline*  OR  xanthin*  OR  m
ethylxanthin* )   AND  ( child*  OR  adolescent*  OR  infan*  OR  p*ediatric )  
 
Reviewer LC screened titles and abstracts, a second reviewer (IS or DH) 
checked the eligibility of abstracts after initial screening, and full studies 
included in the review. Reference lists were screened for other eligible 
studies.  
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3.2.5 Assessment of risk of bias 
The Cochrane Risk of Bias Tool was applied to each RCT. If a dosing regimen 
was found to demonstrate a superior dosing regiment we used this tool to 
help determine the validity of results.  
 
3.2.6 Data extraction and analysis  
From each study we extracted the loading dose and/or maintenance dose of 
IV theophyllines administered, and whether subsequent doses were adjusted 
based on the results of therapeutic drug monitoring. The age range, number 
of participants and use of concomitant medications was also extracted.  
 
If possible, we intended to conduct a quantitative synthesis by pooling 
studies utilizing similar dosing regimens. Separate meta-analyses for each 
dosing regimen used would allow for a quantitative comparison of effect size 
between studies. If quantitative techniques were not possible due to 
methodological or reporting heterogeneity, or insufficient data, we planned 
for a descriptive analysis correlating pre-specified clinical outcomes to the 
dosing strategies used.  
 
3.3 Results	  
3.3.1 Included Studies  
Our search strategy returned 1764 studies, with 38 full text articles assessed 
for eligibility. We excluded 23 full text articles (appendix) with the remaining 
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14 studies included in this systematic review (Fig 8).  
Fig 8. Search results of the systematic review investigating aminophylline 
dosage   
No RCTs comparing dosing strategies for IV aminophylline in children 
suffering an exacerbation of asthma were identified. We therefore included 14 
RCTs comparing aminophylline to placebo (n=10) or β2 adrenergic agonists 
(n=4).  
 
3.3.2 Risk of Bias of Included Studies  
The results from the Cochrane risk of bias assessment are shown in Fig 9. A 
high risk of selection bias was found in one study [98], performance bias was 
found in two studies [90,99], attrition bias in six studies 
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[90,94,95,97,109,110] and reporting bias in two studies [94,98]. All other 
domains were found to have a low or unclear risk of bias.  
Fig 9. Results of assessment of risk of bias of included studies investigating 
the optimum dosage of intravenous aminophylline in children 
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3.3.3 Study Characteristics   
Studies were grouped based on whether they compared aminophylline to 
placebo or β2 adrenergic agonist. The loading doses, maintenance doses and 
clinical outcomes are shown in Tables 1 and 2 
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3.3.4 Aminophylline doses 
The doses given to children across RCTs utilizing IV aminophylline for an acute 
exacerbation of asthma in children is highly variable. All but one study [91] 
prescribes aminophylline as a loading dose followed by an infusion. All studies 
calculate doses based on the actual weight (rather than optimal weight) of individual 
participants, it is not clear in any study whether these were based on actual weight, 
estimated weight or ideal weight of a child. Loading doses range from 4-10mg/kg 
and infusion rates range from 0.5-1.2mg/kg/hr.  
 
Age was factored into dosing strategies of aminophylline in eight studies. Age 
influenced both the loading dose and the infusion rate given in one study [90], with 
the remaining seven studies using age adjusted maintenance doses only 
[91,92,94,95,97,99,109]. In most studies, younger patients received higher doses of 
IV aminophylline.   
 
The results of therapeutic drug monitoring (TDM) factored into aminophylline dosage 
calculations in the majority of studies. Infusion rates were adjusted based to keep 
serum theophylline levels within a predefined range in nine studies [90,92,94-
98,109,111]. In two studies [96,98] serum theophylline levels were factored into 
loading dose calculations.  
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3.3.5 Primary Outcomes 
1) Time until resolution of symptoms Symptom resolution was reported in 
seven studies comparing aminophylline to placebo. Asthma score after a given time 
was reported in four studies [90,94,96,98] and time to reach a predefined asthma 
score was reported in three studies [92,99,112]. All four studies comparing 
aminophylline to β2 adrenergic agonist reported symptom resolution as an outcome. 
This was reported as time to reach a predefined asthma score in one [109], change 
in asthma score in two [110,111] and the proportion of patients in each group 
achieving a low asthma [113]. 
 
There appeared to be no discernible relationship between aminophylline dosage and 
improvement in symptoms. Although one study reported quicker improvement in 
asthma score with a loading dose of 7mg/kg followed by an infusion of 0.5-
0.65mg/kg/hr (time to reach CAS≤3 in aminophylline vs placebo group 18.6±12.0 h 
vs 31.1±20.1 h; [p=0.0238]) [99], this finding is not replicated in studies using 
similar doses despite similar patient cohorts [90,92]. Intravenous aminophylline at 
any dose was equally effective when compared to β2 adrenergic agonist at improving 
symptoms. Due to the differences in methodologies of measuring symptoms, 
statistical pooling of data for time until resolution of symptoms was not possible.  
 
2) Need for mechanical ventilation. No studies comparing aminophylline to 
placebo assessed effect of IV aminophylline against placebo, in non-intubated 
children, on the subsequent need for mechanical ventilation.  One study comparing a 
5mg/kg loading dose followed by an infusion of 0.9mg/kg/h to β2 adrenergic agonist, 
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found a that one subject in the aminophylline group and 2 in the β2 adrenergic 
agonist group required mechanical ventilation [p>0.05] [111] however it is not 
possible to compare this finding with other doses given.  
 
3) Mortality. There were no reported deaths in any study  
3.3.6 Secondary outcomes  
1) Time until discharge criteria are met. Time until discharge criteria are met 
was reported in three studies comparing aminophylline to placebo, one using a 
7mg/kg loading dose followed by an infusion of 0.5-0.8mg/kg/hr [99] and one using 
a 6mg/kg loading dose followed by an infusion rate of 0.85-1.0mg/kg/hr [92], and 
one adjusting loading and maintenance doses based on age  [89]. No studies 
reported a significant improvement in time until discharge criteria are met with the 
use of intravenous aminophylline at any dose. One study reported an improvement 
in the very small subset of patients who were intubated prior to enrolment 
74.8±15.4 in theophylline group vs 189.3±59.8 in control p=0.0325 [99]. 
 
2) Actual discharge. Length of stay was reported in five studies comparing 
aminophylline to placebo [91,95,97-99] and one study comparing aminophylline to 
β2 adrenergic agonists [111]. Four studies reported the number of days spent in 
hospital [95,97-99] one study reported the number of hours spent in the paediatric 
emergency room, [91] and one study reported the number of hours spent in hospital 
[111]. No statistically significant difference was observed in shortening hospital 
length of stay at any dose of aminophylline when compared with placebo.  A loading 
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dose of 5mg/kg followed by an infusion of 0.9mg/kg/h was shown to significantly 
shorten hospital stay compared with β2 adrenergic agonist (57.3h±43.3 vs 
85.4h±56.0 [p=0.02]) [111]. 
 
3) Adverse effects. Adverse effects were compared in six studies comparing 
aminophylline to placebo [92,94-98] and no studies comparing aminophylline to β2 
adrenergic agonist. 
 
There appears to be a higher rate of adverse effects (nausea and vomiting in 
particular) in participants receiving higher loading doses. A significantly higher rate 
of adverse effects was reported in two studies using a loading dose of 10mg/kg and 
7mg/kg [95,97] but not in studies using loading doses between 5-6mg/kg  
[91,93,98,117]. One study reported a higher rate of adverse effects in subjects 
receiving a loading dose calculated using 500ml/kg X change in serum level formula 
[96]. 
3.4 Discussion 
We found no correlation between dosage of intravenous aminophylline in and 
symptom resolution in children suffering an acute exacerbation of asthma. We did 
not identify any studies that assessed the effect of aminophylline on the need for 
mechanical ventilation or mortality. There is no correlation between dose and length 
of stay, and there is weak evidence to suggest that loading doses above 7mg/kg 
result in a higher rate of nausea and vomiting.   There is no evidence to indicate that 
adjustment of dose based on age or serum theophylline levels increases the efficacy 
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or safety of IV aminophylline.  
No RCTs have directly compared dosing strategies for aminophylline when used for 
acute asthma exacerbations in children. The indirect evidence from RCTs comparing 
aminophylline with placebo demonstrates no clear relationship between dosage 
regimen, which varies across studies, and clinical efficacy and safety. The majority of 
dosing strategies aim to achieve serum theophylline levels within a predefined 
range, but this did not translate into clinical improvement.   
Forming dosing recommendations for IV aminophylline in children is complex as the 
drug is used in a wide age range of children with highly variable pharmacokinetic 
properties. Although efforts to account for this variability are reflected in dosing 
adjustments made for age, weight and previous theophylline levels, it is unclear 
whether these adjustments play a significant role in improving the clinical outcomes 
of children with acute asthma. Dosing strategies based on evidence of clinical 
improvement are an important factor when comparing the efficacy of intravenous 
bronchodilators for the treatment of childhood asthma. There is a need for research 
linking the pharmacokinetic knowledge of theophylline, with clinically relevant 
outcomes in acute asthma in children.  
The available data on which to base aminophylline dosage in children are sparse. 
Pharmacokinetic studies allow for the calculation of important parameters in 
calculating drug dose, by observing serum drug concentrations achieved and rates of 
elimination. Study designs commonly used in adults are not transferable to the 
paediatric population [78] and few pharmacokinetic studies investigating 
aminophylline disposition are conducted in children due to ethical limitations, 
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practical challenges and a smaller pool of eligible participants. Asthma is a medical 
emergency, which presents technical challenges in undertaking accurate 
pharmacokinetic studies of aminophylline in sick children.  Lower financial incentives 
are a further barrier as the cost of conducting research in children is likely to exceed 
profits [45]. Theoretical dosage calculations based on pharmacokinetic studies are 
vulnerable to large oversimplifications, and cannot adequately account for the high 
interindividual variation in theophylline clearance. The few Pharmacokinetic studies 
investing aminophylline dosages in children use serum theophylline levels as an 
endpoint [104-106]. This has been shown to correlate poorly with outcomes in 
Chapter 1. Future work must measure clinically relevant outcomes when 
investigating optimum doses of aminophylline in children.  
 
As no RCTs compare aminophylline doses in acute asthma, this review is hindered 
by its use of indirect evidence. This study was unable to provide quantitative effect 
sizes using meta analysis techniques due to a heterogeneity in reporting and a lack 
of data. Furthermore, this review included studies spanning a 32 year time period, 
and it is not clear whether administered doses of aminophylline where based on 
ideal, estimated or actual weight. Additionally, intravenous theophylline and 
aminophylline (theophylline with ethyldiamine) were considered together. 
 
3.5 Conclusion  
The optimum dosing strategy for IV aminophylline for children suffering an acute 
exacerbation of asthma is unclear. The recommended 5mg/kg loading dose followed 
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by an infusion of 0.5-1.0mg/kg/hr with adjustments made based on serum 
theophylline levels may not reflect the optimum efficacy of the drug. Appropriate 
paediatric dosage calculations for aminophylline may require adjustments for age, 
weight and previous serum theophylline levels. Pharmacokinetic studies and high 
quality randomised controlled trials comparing dosing strategies are needed to 
improve the provision of IV aminophylline.  
 
3.6 Summary 
As TDM was shown to be a poor predictor of efficacy in Chapter 2, this work aimed 
to investigate a correlation between dosage and outcomes. This systematic review 
found a poor correlation between dose and efficacy. Indirect evidence was used in 
data synthesis as no studies directly comparing doses were identified. As serum 
theophylline levels, dosages prescribed and clinical outcomes are routinely measured 
in clinical practice, a prospective analysis which links both therapeutic drug 
monitoring practices (Chapter 2), dosage (Chapter 3), with clinical outcomes may 
provide further answers on how to maximise the efficacy and safety of intravenous 
aminophylline.   
  	  	   81 
Chapter 4: Pharmacokinetics and 
clinical outcomes of children 
receiving intravenous aminophylline 
for an exacerbation of asthma 
 
4.1 Background 
4.1.1 Linking TDM, Dosage and clinical outcomes  
Previous chapters have found a poor correlation between serum theophylline levels, 
aminophylline dosage and clinically relevant outcomes (Chapters 2 and 3). Current 
research is unable to provide a definitive dosage and monitoring strategy, which 
results in superior outcomes to those recommended in clinical practice. Complex 
guidelines govern the provision of intravenous aminophylline in children (Fig 3, 
Chapter 1) and it is not clear whether these represent optimum prescribing 
practices, or even whether these are followed in clinical practice.  
 
Patients who receive intravenous aminophylline are subject to therapeutic drug 
monitoring following the administration of loading doses, and at regular intervals 
during intravenous infusions. When a hospitalized child requires intravenous 
aminophylline for an asthma exacerbation, the results of therapeutic drug monitoring 
and the dosage of aminophylline prescribed are stored on hospital databases. This 
practice generates child specific pharmacokinetic data in a method that does not 
affect clinical care, or subject children to unnecessary risks associated with 
traditional PK studies [45,114]. A prospective investigation that considers 
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theophylline levels, dosage and clinical outcomes together can be used to develop 
findings from previous Chapters 2 and 3. 
4.1.2 Aim 
This chapter is an audit aiming to investigate whether the guidelines outlined in 
Chapter 1 are followed. We will also assess whether children achieve serum 
concentrations between 10-20mg/l and whether children in this range have superior 
asthma outcomes.  
 
4.2 Method 
4.2.1 Study Design 
We performed a prospective audit of aminophylline usage. Children were eligible if 
they received intravenous aminophylline for an acute exacerbation of asthma at 
Alder Hey Children’s Hospital. We excluded children who were prescribed 
aminophylline for other indications. Hospital computer systems were used to extract 
relevant pharmacy data, including dose of aminophylline administered, serum 
theophylline levels achieved and timing of measurement. This study was registered 
with the clinical audit department, Alder Hey.  
 
4.2.2 Prescribing Practices 
We assessed whether clinicians followed the 2014 Alder Hey prescribing guidelines 
(Chapter 1 fig 4). If a loading dose was required, we assessed whether a 5mg/kg 
bolus was administered, and whether an age appropriate infusion rate was 
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prescribed. We recorded whether children received concomitant intravenous 
salbutamol or magnesium sulphate.  
 
4.2.3 Serum theophylline levels  
We aimed to investigate whether current prescribing practices achieve the purported 
therapeutic range of 10-20mg/l. We collected the serum theophylline levels of 
children post loading and the number of children requiring top up loading doses. We 
also assessed whether serum levels were measured at the correct time.  
 
4.2.4 Clinical outcomes and adverse effects  
We compared the outcomes of children with levels between 10-20mg/l with those 
who were sub/supratherapeutic. Our chosen outcomes were days until salbutamol 
was commenced at five puffs four hourly, days until discharge and days until in 
room air. We also collected data on common adverse effects including 
hypokalaemia, nausea, vomiting, hypoalbuminaemia, tremor and electrocardiogram 
(ECG) changes. Serum levels of children who experienced at least one adverse effect 
were compared with children who suffered no adverse effects.  
 
4.3 Results 
4.3.1 Participants 
Complete data were available for 28 children between July 2014 and April 2016 with 
an average age of 10.3±5.0 years. Over this period, two patients had multiple 
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admissions, one patient was admitted ten times and one patient admitted twice, 
hence there are 38 admissions in total.  
 
4.3.2 Prescribing practices 
All of the 17 children who did not take oral theophylline received the correct loading 
dose of 5mg/kg. The correct initial infusion rates were given in 15 patients 
(1mg/kg/h if under 12 years, 0.5mg/kg/h if over 12 years). Of the two patients who 
received incorrect infusions, one was over 12 received an infusion rate of 1mg/kg/hr, 
and one patient received an infusion rate of 2.5mg/kg/hr. All of these patients 
attended Alder Hey Children’s Hospital only once during this study.  
 
Of the 11 patients who took oral theophylline, 7 required top up loading doses. 
These ranged between 1mg/kg to 10mg/kg (median 5mg/kg). It is unclear how 
these top up loading doses were calculated. An incorrect infusion rate was 
prescribed to 4 (36%) patients. All these errors were due to patients over 12 years 
of age being prescribed an infusion at a rate of 1mg/kg/hr instead of 0.5mg/kg/hr.  
Of 28 children, 22 (79%) received concomitant intravenous magnesium sulphate and 
3 (11%) received intravenous salbutamol. 
 
4.3.3 Serum theophylline levels  
The average serum theophylline level achieved after a 5mg/kg loading dose was 
8.3±2.7mg/kg. Of the 17 patients who received a loading dose, only two achieved 
levels between 10-20mg/l (Fig 10). Levels were measured at 30 minutes in 7 (41%) 
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of the 17 patients, with an average post loading measurement time of 53±43 
minutes. Serum levels were measured at 12 hours in 12 out of the 17 patients who 
did not take oral theophylline. Therapeutic levels were achieved in five patients, one 
patient had levels >20mg/l and six patients were subtherapeutic.  
 
Fig 10. Serum theophylline levels in patients receiving a 5mg/kg loading dose 
 
Each plot represents a patient who received a 5mg/kg loading dose of 
aminophylline, two patients achieved levels between 10-20mg/l 
 
Of the 10 patients who took oral theophylline, only two patients had serum 
theophylline levels between 10-20mg/l on admission (13.2mg/l and 15.3mg/l). All 
other patients had levels below 10mg/l, of the one patient admitted ten times, the 
median serum concentration on admission was 0.5mg/l.  
 
 Of the 16 patients who received top up loading doses, nine achieved serum levels 
between 10-20mg/l, one patient achieved levels >20mg/l, the remaining patients 
were subtherapeutic. Of the patient admitted 10 times, the median serum level post 
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loading was 10.5mg/l (range 7.4mg/l-13.3mg/l). Serum levels were rechecked at 12 
hours in 15 patients, 10 patients achieved levels between 10-20mg/l, two patients 
had levels >20mg/l and three patients had levels <10mg/l.  
 
4.3.4 Clinical Outcomes and adverse effects  
A summary of clinical outcomes is shown in table 10 
Table 10. Clinical outcomes of children receiving intravenous aminophylline  
Outcome  Result (mean±SD) 
Days in hospital  5.6±9.2 
Days until salbutamol five puffs four hourly 3.1±1.5 
Days until in room air 2.7±6.2 
  
Aminophylline infusions were stopped in after three hours in 2/28 children. The 
outcomes of children with maintenance levels >10mg/l at 12 hours were compared 
with subtherapeutic children. The Mann Whitney U test was performed for statistical 
significance (table 11).  
 
Table 11. Comparison of outcomes of patients <10mg/l vs >10mg/l 
Outcome <10mg/l n=6 
>10mg/l 
n=20 p 
Days until 5 puffs 4 
hourly 12.5 16.25 0.336 
Length of stay 
7.9 15.9 0.039 
Days until in room air 19.8 14.6 0.246 
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Children with levels above 10mg/l did not have superior clinical outcomes compared 
to children who were subtherapeutic. Children with serum levels <10mg/l had a 
statistically shorter length of stay compared to those with levels >10mg/l (7.9 vs 
15.9 p=0.039). 
 
Adverse effects were experienced in 57% patients of those receiving intravenous 
aminophylline (Table 12). Hypokalaemia was the most common adverse effect and 
no patients experienced ECG changes. The average serum level in those with no 
suspected side effect vs those with side effect was 15.8mg/l vs 17.1mg/l [p=0.69] 
 
Table 12. Adverse effects in children receiving intravenous aminophylline 
Side effect Frequency (%) 
Hypokalaemia  10 (36) 
Nausea/vomiting 7 (25) 
Hypoalbuminaemia  3 (11) 
Tremor  1 (4) 
ECG changes  0 (0) 
4.4 Discussion 
There is good adherence to the aminophylline dosage and monitoring guidelines for 
children suffering an acute exacerbation of asthma. All children requiring a loading 
dose received the correct 5mg/kg bolus however some children over 12 years of age 
received higher infusion rates than currently recommended. Serum levels >10mg/l 
are achieved in only 12% of patients following initial loading, and the majority of 
children require top up aminophylline doses which may delay treatment response. Of 
the patients with multiple admissions there is consistency with the serum levels 
achieved. The timing of serum theophylline measurement following loading is 
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inconsistent and the precise serum theophylline level 30 minutes after loading is not 
known in many patients.  
 
Children with serum theophylline levels <10mg/l were found to have a significantly 
longer length of stay compared with those >10mg/l (7.9 vs 15.9 p=0.039). Based on 
these findings, a causal link between higher serum levels and worse clinical 
outcomes cannot be established. It is an aminophylline infusion, rather than loading 
that achieves therapeutic levels. Sicker children are less likely to have their infusions 
stopped and therefore achieve levels >10mg/l, whilst children who demonstrate 
clinical improvement are more likely to have aminophylline therapy terminated, 
despite having subtherapeutic serum levels.   
 
The findings from literature investigating the aminophylline pharmacokinetics in 
children following intravenous aminophylline therapy is conflicting. A loading dose of 
5.6 mg/kg has been shown to achieve a concentration of 10 mg/l (n=10) [104] and 
a PK study using a higher loading dose (6 mg/kg) demonstrated similar results (n = 
11) [105]. However, a similar study using the same dosage did not replicate these 
findings and majority of children were still subtherapeutic and required additional 
boluses [106]. 
The findings of this audit are consistent with Chapter 2, which found no correlation 
between serum levels and clinically relevant outcomes. This work reinforces our 
earlier conclusions that TDM of aminophylline is unlikely to maximize its efficacy. A 
previous audit investigating the relationship between serum theophylline levels and 
clinically relevant outcomes in children suffering an acute exacerbation of asthma 
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also found no association between serum theophylline levels and hospital length of 
stay [100]. Limitations of this study include small sample size and an inability to 
assess all potential side effects. The treatment of acute asthma requires several 
medicines with similar adverse effect profiles. As all included children received a 
combination of these medicines it is difficult to establish a causal relationship 
between aminophylline levels and adverse effects. 
4.5 Conclusion 
Despite adequate dosing (5mg/kg), therapeutic levels of intravenous aminophylline 
are not achieved. However, the effectiveness of treatment for acute asthma is no 
worse if aminophylline does not achieve the therapeutic range in the first 12 hours. 
The small sample of included participants means it is difficult to draw conclusions.  
 
4.6 Summary 
Previous chapters have demonstrated that neither theophylline levels nor dosage 
predicts aminophylline efficacy. This chapter linked both TDM results and dosages in 
a prospective analysis. This work found that current recommendations fail 
to achieve levels 10-20mg/l, but reiterated our findings from Chapter 2 
demonstrating that the current therapeutic range does not result in superior asthma 
outcomes. The pharmacokinetics and clinical response of intravenous aminophylline 
remains unpredictable. A better understanding of the mechanisms underlying inter 
individual variation may highlight a subset of patients who benefit most from a 
particular dose and an important step in developing stratified aminophylline 
therapy.   
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Chapter 5: Pharmacogenetics of 
intravenous aminophylline  
 
5.1 Background  
5.1.1 Variability in aminophylline response  
The efficacy of antiasthmatic medicines is not equal among all children [69,115,116]. 
The clinical response to intravenous aminophylline is inconsistent and unpredictable 
in children suffering an acute exacerbation of asthma, even between patients with 
apparently identical phenotypes, severities and environmental triggers [67]. 
Therapeutic drug monitoring represents an effort to tailor aminophylline dosage to 
the pharmacokinetics of an individual, however Chapter 2 demonstrated that these 
practices may not maximise benefit of the drug.  
 
There is a poor understanding of the mechanisms underlying interindividual variation 
in aminophylline metabolism and the relationship between pharmacokinetics, 
pharmacodynamics and clinical variability remains unclear. If stratified aminophylline 
therapy is to enter routine clinical practice, there is a need for better understanding 
of the precise mechanisms underlying these differences.  
 
CYP1A2 is an enzyme that catalyzes the breakdown of theophylline (the active 
ingredient in aminophylline) into pharmacologically inactive compounds [63] 
(Chapter 1). Variation of the CYP1A2 gene may influence aminophylline disposition, 
which may affect the serum theophylline levels achieved in an individual [117]. A 
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single nucleotide polymorphism (SNP) is a variation in a single nucleotide occurring 
in a specific position in the genome, with a population frequency greater than 1% 
[118]. More than 40 SNPs have been described in CYP1A2, the most extensively 
studied being CYP1A2*1A (wild type), *1C, *1F and *1J [117]. The frequency of 
these variants differs by ethnicity, and the precise allele frequency is not known in 
Caucasians.  
 
Caffeine is a substrate of CYP1A2, and is commonly used as a probe to conduct in 
vivo phenotyping [119]. Though the effect of differing CYP1A2 polymorphisms on 
the rate of enzyme activity has been demonstrated [120,121], how this translates 
into clinical effects is not known. A specific investigation into the link between 
genetics and clinical efficacy is needed to determine whether genotyping CYP1A2 
polymorphisms can act as a potential biomarker for stratified asthma therapy. 
 
5.1.2 Aim 
To determine the effect of CYP1A2 polymorphisms on the clinical outcomes and 
pharmacokinetics of children with an acute exacerbation of asthma receiving 
intravenous aminophylline. 
5.2 Methods  
5.2.1 Study Design 
This chapter describes the initial stages a pilot cohort study comparing the outcomes 
of children receiving aminophylline for an acute exacerbation of asthma based 
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CYP1A2 polymorphisms. Children with wild type CYP1A2 (CYP1A2*1A) were 
compared to those with other polymorphisms (CYP1A2*1B, CYP1A2*1C etc). This is 
an on-going study that will recruit beyond completion of this MPhil. 
5.2.2 Study Population 
Children who presented to the emergency department with an acute exacerbation of 
asthma between August 2015 and May 2016 were eligible for this study. Eligible 
participants were those who attend regular asthma clinics in Alder Hey Children’s 
Hospital. Following recruitment in asthma clinic in April/May 2016, the families of 
patients were interviewed and permission sought to retrieve hospital records.  
 
A DNA sample was collected from saliva or blood. Saliva samples were the default 
collection method for DNA using Noragen’s Saliva DNA reagent kit. However, if the 
participant was due to have a finger-prick blood test, venepuncture or blood test 
taken from a central venous line, as part of routine clinical care we planned to 
collect DNA via whole blood. 
 
5.2.3 Laboratory analysis 
DNA was extracted at the Wolfson Centre for Personalised Medicine, University of 
Liverpool. A candidate gene approach was used to identify polymorphisms within 
CYP1A2.  
 
The following procedure for isolating DNA from 4mL of preserved saliva samples was 
followed. Saliva samples were mixed by inversion and 4ml of the sample was 
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transferred to a centrifuge tube. Proteinase K was added (150 µL), then the sample 
was then vortexted for 10 seconds and incubated at 55 degrees for 15 minutes. 
Following incubation, Binding buffer B was added (1.6ml), the sample was vortexed 
for a further 10 seconds and incubated again at 55 degrees for 15 minutes. Room 
temperature isopropanol was added (1.6ml) and the sample was mixed by inversion 
ten times. After the sample was centrifuged for 10 minutes at 4,000 RPM, the 
supernatant was removed and 70% ethanol was added. The sample was centrifuged 
for further five minutes, the ethanol removed and the sample rehydrated in TE 
buffer. 
 
Patients were genotyped for CYP1A2 polymorphisms using TaqMan relative 
polymerase chain reaction SNP genotyping assays, with genotyping master mix 
(Applied Biosistems, Carlsbad, California). Genomic DNA was genotyped using an 
ABI 7900HT real-time PCR system. All samples were run in duplicate to ensure 
concordance of the genotype. 
 
5.2.4 Outcomes 
The paediatric respiratory assessment measure (PRAM) is used to assess the 
severity of an acute exacerbation of asthma for the entire paediatric age span [122]. 
Although PRAM is externally validated, is not routinely used in clinical practice to 
assess asthma (Table 13). Data was extracted from the hospital meditech™ 
computer system, however If complete PRAM scores were not available, the 
maximum PRAM score that could be achieved based on recorded information was 
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calculated, and divided this by the actual PRAM score measured. We also aimed to 
compare length of hospital stay, number of days the until the patient was no longer 
dependent on oxygen therapy, the number of days until the patient required no 
more than five puffs of inhaled salbutamol every four hours, adverse effects and 
serum theophylline levels (in mg/l). Case record forms were developed for recording 
patient data (appendix).  
 
Table 13. The paediatric respiratory assessment measure  
 Scoring 
Sign 0 1 2 3 
Suprasternal 
retractions 
None  Present  
Scalene 
muscle 
activity 
None  Present  
Air entry Normal Decreased at 
bases 
Diffusely 
decreased 
Minimal or 
absent 
Wheezing None Expiratory 
only 
Inspiratory 
and 
expiratory 
Audible 
without 
stethoscope 
or silent chest 
Pulse oxygen 
saturation  
95% or 
higher 
92%-94% <92%  
 
5.2.5 Environmental Factors 
Participants and their families were interviewed to assess exposure to environmental 
inducers of CYP1A2 enzymes. Smoking status and pack years of patients and 
cohabitants was assessed. Pharmacy records were retrieved for drugs that are 
known to induce or inhibit CYP1A2 (Fig 11).  
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Fig 11. Inducers and inhibitors of CYP1A2 [52] 
Enzyme inducing drugs: 
 Insulin 
Methylcholanthrene 
Modafinil 
Nafcillin 
Naphthoflavone 
omeprazole 
 
 
 
 
Enzyme inhibiting drugs: 
Amiodarone 
Cimetidine 
Ciprofloxacin 
Fluoroquinolones 
Fluvoxamine 
Furafylline 
Interferon 
Methoxsalen 
Mibefradil 
Ticlopidine 
5.2.6 Sample Size 
To achieve a 90% power difference in the domains of days until discharge, days 
until on room air and adverse effects, 272, 56 and 58 patients were needed 
respectively. This calculation has been derived using multiple regression modelling 
from previously collected audit data and a previous study investigating the effect of 
CYP1A2 polymorphisms on theophylline levels [123]. This is pilot work for a larger 
scale study. 
 
5.2.7 Statistical Analysis 
We aimed to perform multivariate analysis and logistic regression modelling to 
examine the impact of CYP1A2 polymorphisms on the outcomes under investigation. 
Any statistical difference between genotype (p<0.05) would be flagged, and the 
difference explored.  
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5.3.8 Ethical Approval 
This project is part of the Molecular Genetics of Adverse Drug Reactions in Children 
(MAGIC) study and has ethical approval. Research Ethics No: 10/H1002/57 
5.3 Results	  
5.3.1 Characteristics of study participants  
A total of seven patients were recruited to the study. A DNA sample was unable to 
be collected in one patient, meaning six patients were included in this study (Fig 12).  
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Fig 12. Included participants in the cohort study  
 
This study included three girls and three boys, with an average age of 11.3±3.0 
years. Three patients were of White British ethnic origin, one patient of mixed White 
British and Black African origin, one patient of Algerian origin and one patient of 
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Pakistani origin. Two patients were exposed to environmental smoke and no patients 
were prescribed enzyme inducing medicines (Table 14).  
 
Table 14. Characteristics of study participants in the cohort study  
ID	   CYP1A2	  Polymorphism	   Age	   Sex	  
Weight	  
(kg)	   Ethnicity	  
Oral	  
theophy
lline	  
Exposure	  to	  
cigarette	  
smoke	  
A	   CYP1A2*1A	   15	   F	   33.0	   White	  British	   Yes	   No	  
B	   CYP1A2*1A	   10	   F	   25.2	   Algerian	  	   No	   No	  
C	   CYP1A2*1A	   9	   M	   27.5	   Pakistani	   No	   No	  
D	   CYP1A2*1A	   15	   F	   80.1	   White	  British	   Yes	   Yes	  
E	   CYP1A2*1A	   11	   M	   33.8	   White	  British	   No	   Yes	  
F	   CYP1A2*1F	   8	   M	   28.5	   Mixed	  	   Yes	   No	  
Blue: wild type cohort, Red: non wild type cohort  
 
5.3.2 Genotyping  
A normal allelic discrimination plot was generated for SNP genotyping (fig 3). Allele X 
was the CYP1A2*1A polymorphism, whilst allele Y was any other CYP1A2 
polymorphism. The blue plots in the upper right hand corner represent the five 
patients with the CYP1A2*1A polymorphism whilst the red plots represent the one 
patient did not have a wild type polymorphism (Fig 13). Further analysis found this 
patient to have the CYP1A2*1F polymorphism. Each patient is represented by two 
plots, as all samples were run in duplicate.  
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Fig 13. Allelic Discrimination plot 
 
Allele X CYP1A2 Polymorphism, Allele Y other, NTC no template control 
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5.3.3 Outcomes  
PRAM score and clinical improvement  
Insufficient data was recorded for complete calculations of PRAM scores. Initial 
assessment prior to aminophylline therapy was more detailed than subsequent 
assessment meaning comparison before and after treatment could not be made. The 
average pram score of patients with the wild type polymorphism was 77.4±22% 
whilst the PRAM score of the patient with CYP1A2*1F polymorphism was 67%. Poor 
subsequent recording of improvement means PRAM scores following aminophylline 
treatment were unable to be calculated. 
  
Length of stay 
The average length of stay in patients with the wild type polymorphism was 5.2±1.5 
days, the one patient with the CYP1A2*1F polymorphism had a length of stay of 
three days. 
 
Days until salbutamol five puffs four hourly and days until in room air 
These outcomes were not recorded on the hospital computer systems 
 
Adverse effects  
Adverse effects were reported in one patient with wild type CYP1A2. This patient 
experienced vomiting and abdominal pain and required an ondeansetron prescription 
for nausea. The patient with CYP1A2*1F had no documented adverse effects.  
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Days until in room air and days till salbutamol five puffs four hourly are poorly 
documented. Clinical outcomes are shown in Table 15.  
Table 15. Clinical outcomes of children included in the cohort study   
Admission	   Initial	  PRAM	  
Max	  
PRAM	  
%	  PRAM	  
score	  
Clinical	  
improvement	  
in	  first	  12	  
hours	  
Length	  
of	  stay	  
(days)	  
Adverse	  effects	  
A.1	   NR	   NR	   NR	   Yes	   4	   Hypokalaemia	  
B.1	   6	   6	  
100%	  
Yes	   5	  
Nausea,	  
abdominal	  pain	  
C.1	   2	   4	   50%	   No	   7	   NR	  
D.1	   4	   6	   67%	   Yes	   4	   NR	  
D.2	   6	   6	   100%	   Yes	   7	   Nausea	  
E.1	   7	   10	   70%	   Yes	   4	   NR	  
F.1	   4	   6	   67%	   Unclear	   3	   NR	  
NR None reported  
Blue: wild type cohort, Red: non wild type cohort  
 
Serum theophylline levels  
The results of serum theophylline levels are shown in Table 16 
Table 16. Serum theophylline levels achieved of included participants in the cohort 
study  
Admission	  
Admission	  
theophylline	  
level	  (mg/l)	  
mg/kg	  
Serum	  
level	  post	  
loading	  
Serum	  
theophylline	  
level	  at	  12	  
hours	  
A.1	   <1	   4.8	   8.9	   12.3	  
B.1	   0	   5	   OC	   10	  
C.1	   0	   5.1	   11.4	   17.9	  
D.1	   OC	   0.5	   15.3	   13.8	  
D.2	   <2.0	   1.8	   8.7	   13.2	  
E.1	   0	   5.5	   8.9	   18.1	  
F.1	   <1	   4.7	   OC	   11	  
OC order cancelled  
Blue: wild type cohort, Red, non wild type cohort 
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All patients with wild type polymorphisms received loading doses or top up loading 
doses. These ranged from 0.5mg/kg to 5.1mg/kg, the average post loading serum 
concentration was 10.6±2.9mg/l and the average maintenance theophylline 
concentration was 14.2±3.2mg/l. The patient with CYP1A2*1F polymorphism 
received a 5mg/kg loading dose, however the serum theophylline level post loading 
was not reported. This patient achieved a serum theophylline concentration of 
11.0mg/l at 12 hours. This patient was not exposed to any known environmental 
inducers.  
 
5.4 Discussion 
This is an on going study and has not yet recruited sufficient participants to assess 
the effect of CYP1A2 polymorphisms on the clinical effects, or pharmacokinetics of 
intravenous aminophylline in children. When further participants are recruited, the 
indirect effects of environmental inducers such as smoking on clinical outcomes will 
be evaluated. 
 
Demonstrating a relationship between genome and clinical efficacy is a crucial stage 
in developing pharmacogenomic information that can benefit patients. If an 
association between CYP1A2 polymorphisms and asthma outcomes is found, this 
would support the use genotyping in stratifying aminophylline therapy in children. 
This would be used as a companion diagnostic to identify of a subset of patients who 
benefit most from intravenous aminophylline. The ultimate goal of this process is 
predictive, pre-emptive personalized asthma care.  
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The effects of differing CYP1A2 polymorphisms on theophylline metabolism are 
poorly understood. Studies investigating this relationship are inconsistent, with some 
studies demonstrating an effect of the *1F/*1F polymorphism on expression and 
higher inducibility of CYP1A2 [123,124], whilst another study shows conflicting 
results [125]. This inconsistency may be due to hidden biases and study design 
limitations resulting in inconclusive findings. These studies use theophylline as a 
probe to measure CYP1A2 activity, but do not address how these differences 
translate into variable treatment response.  
 
Case study evidence shows the effect of CYP1A2 polymorphisms on the side effect 
profile of patients taking clozapine [126], and this is the first study aiming to assess 
how CYP1A2 polymorphisms may alter the clinical efficacy of intravenous 
aminophylline in children. This current work represents a pilot study, and is not yet 
sufficiently powered to have clinically relevant conclusions.  
 
This study is limited by its retrospective use of PRAM scores, as many important 
measurements such as scalene muscle activity are not recorded on patients notes, 
meaning most patient scores are incomplete. Future studies investigating the effect 
of genes on patient response to medicines will need to be prospective, to allow prior 
determination of clinically relevant outcomes, and rigorous surveillance of adverse 
effects. Furthermore, this work is unable to account for the all the complex genetic 
and environmental factors that may play a role in drug response. 
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Pharmacogenomics must go beyond laboratory measurements if it is to enter the 
treatment paradigm of asthma. As the concentration-response relationship for 
intravenous aminophylline is unclear (Chapter 2) future research into aminophylline 
pharmacogenomics should integrate clinically relevant outcomes with 
pharmacokinetic data.  
 
5.5 Conclusion  
Interindividual variation in aminophylline pharmacokinetics and pharmacodynamics 
remains poorly understood. This study forms pilot work for a larger scale study and 
is in its initial stages. It is the first study investigating the link between CYP1A2 
polymorphisms and clinical effects. Further research investigating the genetic 
determinants of drug response is needed.  
 
5.6 Summary  
Previous chapters have demonstrated that serum theophylline levels are poor 
predictors of asthma outcomes. This chapter aimed to investigate the genetic 
determinants of aminophylline response of children suffering an asthma 
exacerbation. An ongoing cohort study has been developed which aims to assess to 
role of CYP1A2 polymorphisms on the clinical response of aminophylline. Upon 
completion, this work may be the initial stages of developing stratified aminophylline 
treatment algorithms.  
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Chapter 6: Discussion and Future 
Work 
 
6.1 Main findings  
This work aimed to assess the evidence base for the recommended dosage and 
monitoring strategies of intravenous aminophylline in children. In this chapter, we 
will discuss the main implications of our findings and highlight areas for future 
research.  
 
There is a lack of evidence for the dosage and monitoring strategies of intravenous 
aminophylline in paediatric asthma management. We found no evidence supporting 
the recommended therapeutic range of 10-20mg/l and a poor correlation between 
dosage and efficacy. There is no clear strategy of stratifying aminophylline dosage 
based on age, weight or serum theophylline levels that maximises its efficacy in 
acute asthma. Despite good adherence to prescribing guidelines, most children do 
not achieve serum theophylline levels over 10mg/l. However, our small retrospective 
study demonstrated that the effectiveness of treatment for acute asthma is no worse 
if the therapeutic range is not achieved within the first 12 hours. We also found that 
children with serum theophylline levels over 10mg/l have a significantly longer 
length of stay in hospital compared with children who are ‘subtherapeutic’. Our pilot 
pharmacogenomic has not yet recruited sufficient participants to assess the 
association between different CYP1A2 polymorphisms and aminophylline clearance in 
children. A summary of thesis findings is shown in Table 17.  
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Table 17. Summary of thesis findings  
Ch. Aim Method Findings  
2 Review the evidence 
base for the therapeutic 
range 10-20mg/l 
Systematic 
review 
 
There is no evidence regarding the 
optimum target range of 10-20mg/l in 
childhood asthma exacerbations  
3 Review the evidence for 
currently recommended 
dosage guidelines  
Systematic 
review  
Current dosing strategies do not 
maximise the efficacy of intravenous 
aminophylline  
4 Assess how 
aminophylline is given in 
clinical practice 
Audit Current dosing strategies do not achieve 
therapeutic theophylline levels, children 
within the therapeutic range do not have 
superior clinical outcomes  
5 Assess the association 
between CYP1A2 and 
aminophylline efficacy  
Cohort 
study 
Study in preliminary stage, effect of 
CYP1A2 unable to be assessed  
 
6.2 Improving Therapeutic Drug Monitoring Practice  
Optimum implementation of TDM requires an understanding of pharmacokinetics. 
Simply relating a drug concentration to a predefined therapeutic range is not 
adequate interpretation, and is unlikely to maximize the benefit of intravenous 
aminophylline [88]. The integration of serum drug concentrations into clinical 
decisions requires the prior demonstration of a concentration-response relationship. 
If a clinically relevant target range is established, pharmacokinetic studies are 
needed to investigate how to achieve target levels through dosing. Understanding 
the variability in drug clearance rates will help develop dosing strategies that are 
tailored to meet the needs of individual patients. This work has found a lack of 
understanding in each of these domains, which is a major barrier to maximizing TDM 
of IV aminophylline. 
TDM is a medical intervention with risks and benefits, and its use in clinical practice 
requires clear evidence of patient improvement. Inappropriate use of TDM results in 
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unnecessary painful blood tests, an over reliance on laboratory measurements and 
laboratory costs. This work has highlighted a lack of understanding of aminophylline 
pharmacokinetics, meaning the relevance of a serum theophylline concentration in 
the context of an acute exacerbation of asthma is unclear. This leads to a clinical 
dilemma, as children can appear to improve despite sub therapeutic concentrations, 
or experience side effects despite serum levels being within the therapeutic range 
(Chapter 2). Knowledge of how to maximize efficacy though dosing is lacking 
(Chapter 3) and currently recommended doses fail to achieve therapeutic levels 
(Chapter 4). In light of these findings, it is not known whether children benefit from 
aminophylline TDM versus clinical assessment alone. No randomized controlled trial 
has compared asthma outcomes of children who receive TDM versus clinical 
assessment alone, and systematic review data has shown a lack of efficacy of TDM 
improving patient related outcomes [127]. 
 
Though the effect of TDM on patient response to aminophylline is unclear, it may 
have other clinically relevant applications relevant for the 21st century. TDM 
technology can be used as a phenotyping procedure to identify slow and fast 
metabolizers, [128] or to investigate non-response to asthma therapy.  
 
6.3 Developing evidence based therapeutic ranges  
For TDM to have relevant application in clinical practice, the upper and lower 
boundaries of the therapeutic range should be determined by the extent of harm 
and benefit respectively. Chapter 2 was unable to provide a clear target range for 
  	  	   108 
aminophylline that maximises efficacy and safety. The lack of primary studies 
investigating the optimum therapeutic range of aminophylline and a poor 
understanding of its pharmacokinetics in children are further hindrances to 
developing evidence based therapeutic ranges. A specific investigation into the 
optimum serum concentrations of aminophylline is required.  
 
A systematic review is the most robust method for evaluating the existing literature 
around the upper and lower limits of the therapeutic range for a particular drug. 
Whilst systematic review methods are well established for studies of efficacy or 
harm, there is no consensus on the optimum methodology for determining 
therapeutic range for a particular drug. Systematic reviews of TDM practice are an 
emerging and uncertain field [129-136], but have the potential to be highly relevant 
with the advent of stratified medicine and individualised treatment. There are 
significant methodological variations as well as inconsistences in the reporting of 
existing published systematic reviews of TDM, and there is clearly a need to improve 
or standardize methods. A peer-reviewed protocol for conducting systematic reviews 
of therapeutic ranges has the potential to benefit patients receiving drugs that 
require therapeutic drug monitoring.   
 
The findings in Chapter 2 are not generalizable to the therapeutic range of oral 
theophyllines for chronic asthma. As relevant outcomes differ between indications, a 
separate investigation would provide further information on the TDM practices in 
long term asthma care.  
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As the evidence base for many therapeutic ranges is poor (Table 18), developing a 
systematic review protocol has the potential to improve monitoring strategies for a 
wide range of drugs for several indications. 
Table 18. Issues with the current evidence base surrounding therapeutic ranges. 
Drug Indications Range 
BNFc 
Evidence Base 
Phenytoin Seizure 
treatment and 
prophylaxis 
10-20mg/l Improvements of EEG at 
levels >10mg/l Buchthal 
1960 and appearance of 
nystagmus at 20mg/l 
(n=12) 
Carbamazepine Seizure 
treatment and 
prophylaxis, 
neuropathic 
pain, 
psychiatric 
indications  
4–12 mg/l  Based on seizure control of 
adults over 21 days n=45 
Cereghino 1974 
Gentamicin Gram negative 
bacterial 
infections 
5–10 mg/l Arbitrary therapeutic range   
Begg 1999 
Teicoplanin Antibiotic 
against gram 
positive 
bacteria 
15-60mg/l Arbitrary therapeutic range 
Begg 1999 
Lithium Treatment and 
prophylaxis of 
mania, bipolar 
disorder, 
recurrent 
depression, 
aggressive or 
self-harming 
behaviour 
0.4–
1 mmol/l 
Based on the treatment of 
acute mania after 7-10 days 
of treatment n=68 Stokes 
1976 A review of 5 studies 
recommends lower levels 
Severus 2008 
Digoxin Atrial 
fibrillation 
Heart failure  
0.8 to 2.0 
ng/ml* 
Upper limit based on only 4 
types of adverse effect 
n=131 Smith 1970 
Theophylline Reversible 
airways 
disease  
10-20mg/l Based on an improvement 
of spirometry from 
participants not suffering an 
acute exacerbation 
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Indirect evidence is was an important resource in gaining further insight into the 
practical applications of TDM and dosage in Chapters 2 and 3. Indirect evidence may 
provide important answers to clinical questions, and guide future research goals in 
areas where there is a lack of primary research such as paediatric pharmacology. To 
maximize benefit from indirect evidence there is a need to improve reporting in 
primary studies. This includes better reporting of TDM results achieved, the use of 
laboratory techniques for determining serum concentrations, using an a priori 
technique for assessing adverse effects and the development of a risk of bias tool for 
use in systematic reviews of therapeutic ranges. 
 
6.4 Stratifying dosage: Beyond one size fits all 
Aminophylline is prescribed to a wide age range of children at different stages of 
development, which may affect its pharmacokinetics and 
pharmacodynamics. Standardized dosing recommendations cannot account for the 
variability in clinical features or severities of acute asthma. Traditional 
pharmacokinetic studies fail to account for the heterogeneity of the paediatric 
population [102,104-106]. These models assume a linear relationship between 
weight and dose and cannot adjust for the rapid changes in rates of organ 
maturation, blood flow, or body composition that take place in childhood. Developing 
stratified dosing will require pharmacological research that is able to account for 
interindividual variation across a population. 
Physiologically based pharmacokinetic modeling (PBPK) can be used to improve 
understanding of drug disposition in children. Computer models can be used to map 
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the complex drug transport scheme onto a physiologically realistic compartmental 
structure. This mathematical model can be used to predict the absorption, 
distribution, metabolism and excretion of aminophylline, and can incorporate 
anatomical and physiological age related changes that take place in childhood. These 
include differing tissue compositions, relative organ weights, blood flow rates and 
the maturation processes of renal and enzymatic function [137,138]. This 
circumvents the ethical issue of recruiting human participants to pharmacokinetic 
studies. PBPK models can also incorporate variability and uncertainty within a 
population, which is necessary when investigating interindividual variation [139].  
PBPK has limited usage in pharmacological research. The inherent complexity and 
unknown phenomenon involved in pharmacokinetics mean PBPK modeling is 
vulnerable to a large degree of oversimplification and the reliability of models to 
predict serum concentrations after the administration of a drug is still unclear [140]. 
There is growing confidence in PBPK as models become more sophisticated and it is 
likely that the results of PBPK will be able to improve paediatric dosing 
in clinical practice. This work contributes foundations for the use of PBPK modeling 
in children receiving intravenous aminophylline [141].  
6.5 Aminophylline pharmacogenomics: from bench to bedside 
A stepwise approach to developing treatment algorithms based on genetic 
information has been proposed (Fig 14), this is a complex multi stage process 
involving various study designs and different levels of evidence [142]. 
Pharmacogenomics has not yet entered routine asthma treatment. This work has 
highlighted practical and methodical challenges in translating hypotheses of genetic 
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association into real life dosing and monitoring adjustments. These include difficulty 
in generating adequately powered studies due to the small pool of eligible 
participants, and challenges in measuring clinically relevant outcomes when relying 
on historical patient records.  
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Fig 14. Stages of developing clinically applicable pharmacogenomics. [142]. 
 
Genes encoding for drug metabolism enzymes are the most widely studied candidate 
genes for pharmacogenomics. This is based on the principle that modulation of 
•  Predicting the variation in efficacy or 
side effects caused by genes coding for 
the drug targets and/or metabolism 
enzymes 
•  E.g. literature reviews, in vitro studies, 
Genome wide association studies to 
identify novel genes which impact 
clinical efficacy 
1) Hypothesis 
generation   
•  Demonstrating an association between 
genetic polymorphisms and clinical 
efficacy 
•  E.g. pilot cohort studies, case control 
studies,  comparing outcomes of 
children with different genotypes.  
2) Hypothesis testing 
and replication 
•  Studies showing a follow on genetic 
association demonstrated in the intial 
hypothesis testing stage. If such an 
association exists, evaluation of its 
clinical significance  
•  E.g. larger scale cohort studies and 
case control studies  
3) Firm Hypothesis 
testing 
•  A risk benefit assessment for 
pharmacogenomic companion 
diagnostics, including the impact of 
therapeutic choice  
•  E.g. randomised controlled trials 
comparing children receiving 
pharmacogenetic companion diagnostic 
to placebo  
4) Clinical trials 
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pharmacokinetics alters drug concentrations in the body, which determines both its 
therapeutic efficacy and adverse effects [143]. If genotyping of drug metabolism 
enzymes is to enter clinical practice, there must be an established relationship 
between serum concentrations and clinical response. Chapter 2 demonstrated that 
currently accepted therapeutic ranges have a poor evidence base, and do not always 
translate into clinical benefit, or prevention of adverse effects. This is a major barrier 
to overcome if genotyping drug metabolism enzymes are developed as companion 
diagnostics in stratifying aminophylline dosing.  
 
There is a need to increase the numbers of participants involved in in the preliminary 
stages of pharmacogenomic research if its findings are to benefit patients. Many 
studies are underpowered because of the low allele frequency of many 
polymorphisms, and identifying relevant cohorts is difficult, as genotyping is not part 
of standard clinical care. Recruitment problems are amplified in paediatrics, where 
there is a smaller pool of eligible participants and a complex consent process [144].  
 
Better understanding of the link between genes and aminophylline variability 
requires an appreciation of the high number of chromosomal regions being 
associated with drug response. There is evidence that variability in the CYP1A2 gene 
affects this disposition of several substrates, but this relationship alone cannot 
provide a comprehensive explanation for the genetic determinants of drug response. 
Interindividual variation is unlikely to be coordinated by a single protein, and there is 
a need to develop pharmacogenomic research beyond drug metabolism enzymes. 
Better understanding of the role of drug transporters, receptors and transduction 
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pathways will provide a more complete picture of the mechanisms underlying 
asthma variability. There is a large number of potential genes that may affect drug 
response, including genes which affect hepatic/renal elimination and genes which 
influence the transport of aminophylline into specific cells. The association between 
these factors and patient response to aminophylline response has not yet been 
investigated.  
 
Findings from studies investigating the role CYP1A2 in developing 
pharmacogenomics are inconsistent [120,121,123-125,145-148]. Lack of 
reproducibility of results from observational studies is a key barrier to understanding 
and confirming the therapeutic relevance of candidate genes. As pharmacogenomics 
is a relatively new discipline there is a need to develop adequate study designs that 
account for the complexity of drug response.  
 
Genome wide association studies (GWAS) may be an important study design in 
generating hypotheses that can be tested and then subsequently translated into 
clinical trials. These seek to identify variations that modify the response to a certain 
drug throughout the entire genome, rather than a single candidate gene. They may 
be useful in investigating pharmacodynamic variability, where the profile of potential 
SNPs influencing drug response is vast. There are distinct advantages and 
disadvantages of this method when compared to candidate gene analyses (Table 
19), and GWAS may be a vital tool in expanding our knowledge of the unknown 
genetic influences on drug response. 
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 Table 19. Candidate gene analysis vs genome wide association studies   
 Candidate gene study Genome wide association study 
Selection of genes SNPs selected by the researcher Whole genome 
Number of genes 
selected Up to 10 SNPs Millions of SNPs 
Use in 
pharmacogenomic 
development 
Hypothesis testing Hypothesis forming 
Cost Lower Higher 
 
 
6.6 Clinical Trials and Stratified Medicine  
Current randomised controlled trials (and thus, systematic reviews) comparing 
aminophylline to placebo lack important analyses that are relevant to stratifying 
asthma therapy. Firstly, the uncertainty surrounding the optimum dosage and 
monitoring strategies is an important confounding factor, and many meta-analyses 
include studies with widely differing administered doses as shown in Chapter 3. 
Secondly, there have been no RCTs that include an investigation of genetic 
differences related to outcomes. As asthma outcomes are analysed according to 
assigned treatment arms, it is likely that study groups were composed of good and 
bad responders. Due to the small pool of eligible study participants in paediatric 
asthma research, it is likely these studies lacked sufficient power related to 
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responsiveness. Appreciation of variability will require large-scale studies that can 
account for the interindividual variation in treatment response. 
 
Only when the potential of intravenous aminophylline is maximised, can it be 
definitively compared to placebo or other treatment in clinical trials. Uncertainty 
regarding its dosage and monitoring means the place of aminophylline therapy in 
acute asthma remains unclear. This will allow evaluation of whether aminophylline is 
a superior treatment to intravenous salbutamol or magnesium sulphate. This thesis 
provides important groundwork for clinical trials that adequately represent the 
optimum risk benefit ratio of intravenous aminophylline in the treatment of an acute 
exacerbation of asthma.  
6.7 Final Conclusion  
Prescribing practices of aminophylline in paediatric acute asthma have a very limited 
scientific rationale. There are major gaps in knowledge in how to maximise 
aminophylline efficacy through therapeutic drug monitoring. Pharmacokinetic studies 
of aminophylline in children are scarce and improving understanding requires 
deriving the maximum content from the limited data in paediatric studies. Stratifying 
asthma therapy is complex and will require research into systematic review 
methodologies and large-scale pharmacogenomic studies. This work provides the 
initial steps towards large-scale studies aiming to assess aminophylline efficacy and 
variability. 
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8 Appendix  
Appendix 1 Excluded Studies  
 
Table 1. Chapter 2, Full text articles excluded with reasons  
Study Reason 
Singhi 2014 [1]  Did not measure theophylline levels  
Zainudin 1994 [2]  Includes adults and children, children not treated 
separately in results and statistical analysis 
Ibrahim 1993 [3]   Did not measure theophylline levels 
Shilalukey 1993 [4]   Did not measure any of the stated primary outcomes 
Bowler 1987 [5]   Adult study 
Carrier 1985 [6]   Adult study 
Katz 1981 [7] Includes adults and children, children not treated 
separately in results and statistical analysis 
Blumenthal 1979 [8] Correspondence article 
Josephson 1979  [9] Includes adults and children, children not treated 
separately in results and statistical analysis 
Hambleton 1979 [10] Did not measure theophylline levels 
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Table 2. Chapter 3, Full text articles excluded with reasons  
Ref. Reason 
Tiwari 2014 [11] No other studies used ketamine as a comparator 
drug. Unable to compare across studies   
Nagao 2007 [12] Supplement article, no full text available  
Alcaraz 2007 [13] Not a randomised controlled trial 
Yamauchi 2005 [14] Adult study  
Emerman 2001} [15] Cohort study  
Tomac 1996 [16] Not an RCT 
McKenzie 1994 [17] Editorial article  
Zainudin 1994 [2] Adult study  
Janson 1992 [18] Adult study  
Vilsvik 1990 [19] Adult study  
Stine 1989 [20] Includes adults and children, not treated separately in 
analysis  
Fanta 1986 [21] Adult study  
Seki 1986 [22] Not an RCT 
Siegel 1985 [23] Supplement article only, full text not available  
Rossing 1981 [24] Adult study  
Goldberg 1980 [25] Not a randomised controlled trial 
Rossing 1980 [26] Adult study  
Evans 1980 [27] Adult study  
Josephson 1980 [28] Adult study  
Wolfe 1978 [29] Adult study  
Tribe 1976 [30] Adult study  
Pierson 1971 [31] Did not report dose  
Fanta 1982 [32] Adult study  
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Please complete the Case Report Form (CRF) as thoroughly as possible 
and then post or fax a photocopy of the completed CRF to the lead 
coordinating centre, along with the anonymised discharge summary 
and/or additional anonymised reports (e.g. skin biopsy reports, CXR, CT 
scan results etc).  
 
 
The structure of the CRF is shown in the following diagram; 
 
 
 
 
 
 
 
 
 
 
 
 
 
All forms should be completed in black ink in a clear manner. Any changes or corrections should be 
made by drawing a line through the data‚ entering the corrected information and initialling and dating 
the change.  
 
Following standard notation should be used in the event that values or answers cannot be provided: 
 
• NA: Not applicable 
 
• NK: Not known 
 
• ND: Not done 
 
• NR: Not retrievable/Not available 
 
Please ensure that when referencing medications and chemicals you detail 
the GENERIC name and not the brand name 
 
 
  
General Guidelines for CRF Completion  
Even	  Pages	  	  Contain	  notes	  on	  how	  to	  complete	  the	  adjacent	   	  odd	  numbered	  page	  	  	  
Odd	  Pages	  	  To	  be	  completed	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Part A Inclusion/Exclusion criteria – Notes 
 
 
[ 1 ] The patient must be given a Patient Information Leaflet and Consent Form to be included in 
the study. If the patient is <16 consent must be granted by Parent or Guardian/Nominated Parent or 
Guardian, else if >16 patient must give consent. 
 
[ 2 ] If the patient is participating in another study, it is essential to discuss eligibility to participate 
with the Principal Investigator prior to ticking “yes” or “no”.  
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Inclusion/Exclusion Criteria 
Please tick ’yes’ or ‘no’ to all questions   
     
 
Exclusion Criteria 
 
Please tick ’yes’ or ‘no’ to all questions   
 
  
A   Yes 
 
No 
1. Patient/Participant willing to take part in study if >16 years of age at recruitment  
 
 
 
2. Patients/Participants parent or guardian willing to consent to study if <16 years of 
age at recruitment 
 
 
 
 
4. Assent obtained from competent young person? (assessed on case by case basis) 
Version [ ___ ] Version dated [ DD / MM / YYYY ]  Date given [ DD / MM / YYYY ] 
 
 
 
 
5. Patient information leaflet read by Patient/Parent or Guardian/Nominated Parent or 
Guardian[1] 
Version [ ___ ] Version dated [ DD / MM / YYYY ]  Date given [ DD / MM / YYYY ] 
 
 
 
 
6. Parent information leaflet read by Parent/guardian? 
Version [ ___ ] Version dated [ DD / MM / YYYY ]  Date given [ DD / MM / YYYY ] 
 
 
 
 
7. Written informed consent obtained? [ 1 ] 
Version [ ___ ] Version dated [ DD / MM / YYYY ]  Date given [ DD / MM / YYYY ] 
 
 
 
 
8. Patient has a diagnosis of asthma   
9. Patient has attended Alder Hey Children’s hospital with an acute exacerbation of 
asthma requiring treatment with intravenous aminophylline  
  
B   Yes 
 
No 
9. Patient/Participant unwilling to take part in study if >16 years of age at 
recruitment 
  
 
10. Patients/Participants parent or guardian unwilling to consent to study if <16 years 
of age at recruitment 
  
 
11. Competent older participant unwilling to assent (competence assessed on a case 
by case basis) 
 
 
 
 
12. Unable to nominate a Parent/Guardian 
 
  
13. Patient is, in the opinion of the Investigator, not suitable to participate in the 
study. 
 
  
       
Patient Eligible for study [ 2 ] Yes   No   
  Patient included in the 
study                    
        Patient Not included  
  Please complete CRF      in the study                    
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Recruitment Information – Notes 
 
 
[ 1 ] Please enter the patient’s date of birth at the time of recruitment. 
 
[ 2 ] Ethnic origin as self reported, by the patient or documented in casenotes. Please note that we 
appreciate it may be difficult to obtain Parents information, so we would be very grateful for any 
information provided. 
 
Please use codes as listed: 
1. White 
2. White Irish 
3. Other White 
4. Mixed: White and Black Caribbean 
5. Mixed: White and Black African 
6. Mixed: White and Asian 
7. Other mixed background 
8. Indian 
9. Pakistani 
10. Bangladeshi 
11. Other Asian background 
12. Caribbean 
13. African 
14. Other Black background 
15. Chinese 
16. Other ethnic group (please specify) 
17. Not Known 
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Recruitment Information 
   
Patient Demographics 
 
  
Sex Male  Female    
  
Date of Birth [ 1 ]    
  
Patient Height                  (2 decimal 
places) 
NK   
  
Patient Weight                   (2 decimal 
places) 
NK   
  
    
 
  
Ethnic origin [ 2 ] 
      Own    Specify  Country of 
Birth 
  
  
Mother   Specify  Country of 
Birth 
  
  
Father   Specify  Country of 
Birth 
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[ 1 ] Has patient ever had any medical or surgical interventions prior to the recruitment 
visit? 
 
Not Recorded = section not relevant to study arm 
 
  
Previous Medical History - Notes 
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Previous Medical History 
 
 
    
1. Has patient ever had any 
medical or surgical 
problems? [ 1 ] 
Yes  No   Not Recorded   
   
    
    
2. Malignancy Yes  No  Specify   
    
    
3. Respiratory Disease Yes  No  Specify   
    
    
4. Cardiac Disease Yes  No  Specify   
    
    
5. Gastrointestinal Disease Yes  No  Specify   
    
    
6. Neurological Disease  Yes  No  Specify   
         
    
7. Haematological (not 
malignancy) 
Yes  No  Specify   
    
    
8. Immunological Yes  No  Specify   
    
    
9. Endocrine Yes  No  Specify   
    
    
10. Skin Yes  No  Specify   
    
    
11. Eyes Yes  No  Specify   
    
    
12. Ears Yes  No  Specify   
    
    
13. Musculoskeletal  Yes  No  Specify   
    
    
14. Renal Yes  No  Specify   
    
    
15. Psychiatric Yes  No  Specify   
    
    
16. Other Disease Yes  No    
    
  Specify   
    
  Specify   
    
  Specify   
    
  Specify   
    
  Specify   
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 [ 1 ] You will be asked to collect either a blood or saliva sample by the lead co-ordinating centre.  
The quality of the DNA from a blood sample is much higher than from saliva, so we would 
be grateful if you could collect a blood sample from the patient were possible.  
Blood Sample / Saliva Sample Collection - Notes 
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Blood sample / Saliva Sample Collection [1] 
  Blood sample collected for DNA?  
( Purple top EDTA sample, if 
possible please collect 5-9ml. 
Minimum requirement is 2ml) 
Yes  Date & time 
collected 
DD/MM/YYYY – 
HH:MM 
 
  
 Amount collected   
  
 No  Reason not 
collected 
  
     
 N/A    
  
  
  
Saliva sample collected for 
DNA? 
Yes  Date & time 
collected 
DD/MM/YYYY – 
HH:MM 
 
(2mls self collection kit)  
 No  Reason not 
collected 
  
     
 N/A    
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(Part B)Regular medications/chemicals   
 
[ 1 ]  Please detail any regular medications including preventer inhalers, reliever inhalers, topical 
steroids, nasal steroids and leukotriene receptor agonists 
 
 (Please specify the generic name of the Medication/Chemical and NOT the brand name) 
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 (Part B) List of Medications/Chemicals 
  
   Medication  Dose   
   Formulation 
[2] 
 Route [3]  Frequency   
   Start date DD/MM/YYYY Stop date DD/MM/YYYY  
     Medication  Dose   
   Formulation 
[2] 
 Route [3]  Frequency   
   Start date DD/MM/YYYY Stop date DD/MM/YYYY  
     Medication  Dose   
   Formulation 
[2] 
 Route [3]  Frequency   
   Start date DD/MM/YYYY Stop date DD/MM/YYYY  
     Medication  Dose   
   Formulation 
[2] 
 Route [3]  Frequency   
   Start date DD/MM/YYYY Stop date DD/MM/YYYY  
     Medication  Dose   
   Formulation 
[2] 
 Route [3]  Frequency   
   Start date DD/MM/YYYY Stop date DD/MM/YYYY  
     Medication  Dose   
   Formulation 
[2] 
 Route [3]  Frequency   
   Start date DD/MM/YYYY Stop date DD/MM/YYYY  
     Medication  Dose   
   Formulation 
[2] 
 Route [3]  Frequency   
   Start date DD/MM/YYYY Stop date DD/MM/YYYY  
     Medication  Dose   
   Formulation 
[2] 
 Route [3]  Frequency   
   
 
 
Start date DD/MM/YYYY Stop date DD/MM/YYYY  
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[1]  Examples of triggers include animal dander, exercise, stress, pollen, certain 
drugs 
Answer yes if a serum IgE level has been recorded on the alder hey meditech™ 
system 
 
[2]  Refers to metered dose inhalers (MDIs) which give the medicine in a spray form 
(aerosol). Reliever examples include Ventolin, Airomir and Salamol, preventer 
examples include beclometasone dipropionate, budesonide, fluticasone propionate 
and mometasone furoate 
 
[3]  Refers to NHS immunization schedule which applied at the time of birth. A full 
immunization status includes 
• 5-in-1 (DTaP/IPV/Hib)  
• Pneumococcal (PCV) 
• Rotavirus if born before September 2013 
• Meningitis B if born before September 2015 
• Meningitis C 
• Measles Mumps and Rubella (MMR) 
  
Chronic Asthma History - Notes 
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Chronic Asthma History 
    Symptoms Age at onset of symptoms 
   Known triggers [1] Yes  No   
 If yes please tick all that apply 
 Animal fur  Pollen/grass   
       Dietary triggers  Exercise    
       Cold air  Emotion/stress   
       Medicines   Cigarette smoke   
   Other    
  Does the patient have any  Nocturnal cough  Yes  No   
  history of atopic disease? Diagnosis of eczema at any time Yes  No   
        If YES, current eczema Yes  No   
        Hayfever Yes  No   
        Other allergies Yes  No   
   If YES please specify   
   Have IgE levels been measured? 
[2] 
Yes  No   
   If YES: 
 Most recent level  Date DD/MM/YY  
   Highest level  Date DD/MM/YY  
  Asthma maintenance On average, how often is a reliever inhaler used? 
 Monthly  Daily   
       Weekly  Twice Daily   
       Every other day  More than twice daily   
  Spacer device usage When taking a RELIEVER inhaler, how often is a spacer used?  
  Always  Sometimes  Rarely  Never  
          
 When taking a PREVENTER inhaler, how often is a spacer used? 
  Always  Sometimes  Rarely  Never  
          
   Number of courses of oral steroids since August 1st 
2015  
  
  Immunizations [3] Immunisation status  Full  Partial  None   
   Missed immunisations   
  Treatment history Has the patient EVER experienced an asthma attack requiring: 
 IV salbutamol   HDU admission    
       ITU admission  Intubation   
  d 
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Birth History 
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Obstetric history  
  
Gestational age at birth  f Weeks  Days  
  
Birth weight   
  
Was NICU admission required? Yes  No   
  
Was Intubation required? Yes  No   
  
Was Ventilation required? Yes  No   
  
Home oxygen required? Yes  No   
  
Was this a singleton pregnancy? Yes  No   
 If no please state otherwise 
  
 Twin/Triplet/Other (.......................................................) 
  
  
 
  
BIRTH HISTORY 
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[1] Answer yes if the patient shares an address with anyone who smokes at least 
one cigarette a day, whether inside or outside the house 
 
[2] Detailed the combined number of cigarettes smoked by all the smokers with 
whom an address is shared, if the patient lives with only one smoker, this figure will 
be the number of cigarettes smoked by that person.  
 
[3] An electronic cigarette is any device containing a nicotine-based liquid that is 
vaporized and inhaled 
 
[4] Tick yes if the patient shares a house with any domesticated animals including 
dogs, cats, budgerigars, hamsters, gerbils, guinea pigs, ferrets etc 
 
[5] Caffeinated drinks include tea, coffee, Coca-Cola, energy drinks  
 
 
 
 
  
Social History - Notes 
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Social History 
 
 
  1. Smoking history of 
patients  
Does the patient live 
with a smoker? [1] 
Yes  no   
  
   If YES, How many smokers 
does the patient live with 
  
   Total number of cigarettes 
smoked in the house a day [2] 
  
   Does the patient live 
with an electronic 
cigarette user? [3] 
Yes  No   
  
  2. Smoking history of 
patient 
Does the patient 
smoke? 
Yes  No   
  
   If YES how many 
cigarettes a day are 
smoked? 
     
   Does the patient use an 
electronic cigarette? 
Yes  No   
  
  3. Pets  Does a patient live in a 
house with animals [4] 
Yes  No   
  
   If YES Please 
detail  
  
  
4. Caffeine intake Does that patient drink 
caffeinated drinks? [5] 
Yes  No   
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Please detail the most recent short synacthen test  
[1] Adrenal insufficiency is excluded by an incremental rise in cortisol of > 200 
nmol/L and a 30 min value > 600 nmol/L. 
  
Short Synacthen Test - Notes 
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Short Synacthen Test  
 
  
Short Synacthen Test DD/MM/YY 
  
Date  DD/MM/YY  
  
Initial Cortisol level   nmol/L 
  
Dose of Synacthen Given   micrograms 
  
Post synacthen Cortisol level    
  
Adrenal insufficiency [1]  
Yes  No   
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 [1] This form to complete details of the first acute exacerbation requiring IV 
aminophylline which occurred after 16th August 2015. If more than one exacerbation 
has occurred, please use the forms on appendix 1 provided to complete the 2nd, 3rd 
4th exacerbation etc, and any subsequent admissions (second, third, fourth etc) in 
appendix 1. 
  
[2] Oral theophylline includes the following preparations: Uniphyllin Continus®, 
Nuelin SA® 250, Nuelin SA® 175, Slo-Phyllin®, Slo-Phyllin® 
 
[3] ONLY answer this section of the patient takes one of the above medications. 
Leave this section blank if none of these prescribed 
 
[4] ONLY answer if the patient DOES NOT take one of the above medications. Skip 
to maintenance dose section if this is not the case 
 
  
Acute Asthma History  – Serum Levels 
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1 Patients on home 
theophylline 
Date of 
admission 
 Date of 
discharge 
DD/MM/YY  
     Was the patient taking oral theophylline on 
admission? 
Yes  No   
    
  If yes, skip part 3 
   
2 Loading dose What loading dose IV 
aminophylline was given? 
 mg  Time 
started 
HH:MM  
   
  Serum concentration on 
completion of the loading  
 mg/l Time HH:MM  
   
  Serum concentration on 
admission 
 mg/l Time HH:MM 
 
 
   
  If patient was taking home theophylline please skip to part 4 
   
3 Patients not on home  Was a top up loading dose required? Yes  No   
 theophylline If Yes 
  Dose given  mg Time started HH:MM  
   
  Serum concentration post 
top up 
 mg/l Time HH:MM 
 
 
   
4 Maintenance dose  Infusion rate of first infusion  ml/hr 
   
  Subsequent theophylline 
level 
 mg/l Time HH:MM 
 
 
   
  
Acute Asthma History – Serum Levels 
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[1] The paediatric respiratory assessment measure (PRAM) score is as follows 
 Scoring 
Sign 0 1 2 3 
Suprasternal 
retractions 
None  Present  
Scalene 
muscle 
activity 
None  Present  
Air entry Normal Decreased at 
bases 
Diffusely 
decreased 
Minimal or 
absent 
Wheezing None Expiratory 
only 
Inspiratory 
and 
expiratory 
Audible 
without 
stethoscope 
or silent chest 
Pulse oxygen 
saturation  
95% or 
higher 
92%-94% <92%  
Please do not include scaline muscle activity in the assessment, therefore the PRAM 
score will be out of 10 
 
 
  
Acute Asthma History: Clinical Data – Notes 
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Acute Asthma History: Clinical Data  
   Initial assessment  Time HH:MM  
  
PRAM score To be completed as fully as possible 
  Supra sternal retractions None  Present  NK   
          Scalene muscle activity None  Present  NK   
  
 Air entry recorded  Yes  No   
        Normal  Decreased at bases  Diffusely decreased  Absent  
          
          
 Wheezing recorded Yes  No   
 None  Expiratory only  Expiratory & inspiratory   Without steth 
          
          
 Pulse oximetry recorded Yes  No   
 >95%  92%-94%  <92%  
        
  
Paediatric asthma 
emergency  
First review of treatment Time HH:MM  
car  pathway notes Please tick ONE box 
 Improving Unchanged Inadequate response Worsening Discharge 
            
             Second Review of treatment Time HH:MM  
 Please tick ONE box 
 Improving Unchanged Inadequate response Worsening Discharge 
            
   Time transferred from A&E to ward  HH:MM  
  Ward Care Did the patient require any of the following during ENTIRE admission? 
  Yes  No  
 IV Salbutamol    Number of boluses   
       IV magnesium    Number of boluses   
       PICU admission     
       Mechanical ventilation     
       Date of discharge from PICU if admitted DD/MM/YY  
     Date patient was in room air DD/MM/YY  
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[1] Other adverse effects include  
Gastrointestinal 
 Diarrhoea 
Neurological 
 Agitation 
 Hallucination 
 Ataxia 
 Insomnia 
 Confusion 
Cardiovascular 
 Asystole 
Metabolic 
 Ketoacidosis 
 Lactic acidosis 
 Hyper glycaemia 
Miscellaneous 
 Rhabdomyolysis 
 Leucocytosis  
 
[2] 
Enzyme inducing drugs include: 
Insulin 
Methylcholanthrene 
Modafinil 
Nafcillin 
Naphthoflavone 
omeprazole 
Enzyme inhibiting drugs include: 
Amiodarone 
Cimetidine 
Ciprofloxacin 
Fluoroquinolones 
Fluvoxamine 
Furafylline 
Interferon 
Methoxsalen 
Mibefra
Acute Asthma History: Adverse Effects 
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Adverse effects 
[1] 
Did the patient experience a suspected adverse 
effect during this admission? 
Yes  No   
  
 If Yes please detail 
 Group 1 Cardiac Arrhythmias   Seizure   
   Group 2 Nausea  Abdominal pain   
         Agitation/tremor   Hallucinations    
         Other     
        Please detail   
   Serum theophylline level at time of adverse 
effect if known 
 mg/l 
  
Concomitant 
medication [2]  
Was the patient taking enzyme inducing/inhibiting drugs 
at the time of this admission  
Yes  No   
  
   Name of drug 
 
  
  
 
 
 
Name Signature Date 
  
DD/MMM/YYYY 
 
 
 
 
 
 
Acute Asthma History: Adverse Effects 
